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Abstract 
 
 
Members of the solute carrier (SLC) family of transporters govern the cellular influx 
of a multitude of endogenous compounds, xenobiotics and drugs. SLCs including 
OATP1A2 (SLCO1A2), OATP1B3 (SLCO1B3) and OCT1 (SLC22A1) participate in 
the disposition of several anticancer drugs, such as the tyrosine kinase inhibitor (TKI) 
imatinib. The regulation of most solute carrier transporters is modulated in cancer 
cells, hence individuals with altered expression of these proteins may have different 
antitumour efficacy with TKIs that are SLC substrates. Furthermore, some of these 
agents may elicit drug-drug interactions during therapy, so the accumulation of 
pharmacokinetic data concerning TKIs is of clinical interest. 
 
In this project, the impact of TKIs on the uptake of model substrates in cells 
overexpressing SLC transporters was evaluated. Human embryonic kidney 293 
(HEK293) cells were transfected with complementary DNA to express transport 
proteins, including organic anion transporting polypeptides (OATP1A2, OATP1B1, 
OATP1B3 and OATP2B1), organic anion transporters (OAT1-4), organic cation 
transporters (OCT1-3) and organic zwitterion/cation transporters (OCTN1-2). In the 
preliminary screening experiments, TKIs (10 µM) were tested for their capacity to 
inhibit the uptake of a specific transporter-mediated radiolabelled substrate into these 
cells. Half maximal inhibitory concentrations (IC50) and inhibition constants (Ki) of 
potent inhibitors were determined.  
 
Of the 13 clinically relevant TKIs tested, 11 effectively inhibited substrate uptake by 
some transporters. Two of these interactions had IC50 and Ki values in the nanomolar 
ix 
 
range: the inhibition of OATP1A2- and OATP2B1-mediated estrone-3-sulfate uptake 
by cediranib and erlotinib, respectively.  
 
Given that the predicted maximum unbound plasma concentration of cediranib is 6 
nM, this drug has the potential to inhibit OATP1A2-dependent drug transport at 
clinically relevant concentrations, as the unbound IC50 or Ki of cediranib is estimated 
to be approximately 1 nM.  
 
Similarly, erlotinib-induced inhibition of OATP2B1 transport was regarded as 
clinically relevant since the IC50 and Ki values were approximately 10-fold less than 
the maximum unbound plasma concentration achieved by this drug. Interactions of 
OATP1A2 and OATP1B3 with erlotinib were also found to be clinically significant. 
In particular the inhibition of OATP1B3 by erlotinib was suggested for further in vivo 
drug-drug interactions tests, because this transporter is known to transport several 
important anticancer drugs, including paclitaxel and the irinotecan metabolite SN-38, 
which may be used concomitantly with erlotinib in chemotherapy.  
 
Implementing the R value extrapolation approach recommended by the International 
Transporter Consortium (ITC), model substrate uptake inhibition by gefitinib in 
OATP1A2- and OATP2B1-transfected HEK293 cells and neratinib in OATP1B3-
HEK293 cells were additional transporter-TKI interactions found to be potentially 
implicated in in vivo drug-drug interactions. Furthermore, nilotinib and bosutinib 
were identified as inhibitors of OAT3 and OCT1, respectively, and are suggested for 
further clinical drug-drug interaction studies.  
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Chapter 1 
 
Literature Review 
 
 
1.1 Human solute carriers 
 
In recent years, members of the human solute carrier (SLC) classification of proteins 
have become recognised as major intermediaries in the uptake of pharmaceutical 
drugs into cells. The past view that therapeutic and intrinsic compounds are typically 
absorbed by diffusion via the lipid bilayer of the cell membrane has been superseded 
by the knowledge that transport proteins are the predominant means of cellular influx 
for most endogenous and exogenous molecules (1,2). Human organic anion and 
cation membrane transporters are categorised within two SLC gene families; SLCO 
(previously SLC21), consisting of the organic anion transporting polypeptides 
(OATPs), and SLC22, comprising the organic anion transporters (OATs), organic 
cation transporters (OCTs) and organic zwitterion/cation transporters (OCTNs). Some 
SLCs are expressed pervasively throughout the body, such as OCT3 and OCTN1-2 
(3), while others are limited to particular tissues, for example OATP1B1 and 
OATP1B3 in hepatocytes (4), however all play significant roles in drug uptake, 
distribution and elimination (5). Given that members of both SLCO and SLC22 
families are characterised by their broad substrate specificities (6), a multitude of 
drugs, xenobiotics and endogenous compounds can be transported by individual 
proteins. Consequently these uptake transporters may be principal determinants of 
drug disposition and response, and, salient to the focus of this thesis, sites at which 
drug-drug interactions can occur (7).  
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1.1.1 Transporters in the SLCO superfamily: OATPs 
 
OATP research has advanced considerably in the nearly 20 years since the first rat 
and human OATPs were cloned (8,9), with emphasis on determining substrates and 
inhibitors of these transport proteins, in addition to clarifying the effect of 
interindividual variations and cancer on transporter expression and function (10,11). 
 
1.1.1.1 Nomenclature 
 
The SLCO family belongs to the major facilitator superfamily (MFS) of membrane 
transporters. OATPs are classified by their amino acid sequence where the guidelines 
stipulate that proteins with more than 40% sequence identity belong to the same 
family (SLCO or OATP), while proteins with greater than 60% identity are part of the 
same subfamily (for example OATP1, OATP2, OATP3, OATP4, OATP5, and 
OATP6) (12). Each of these groups can have subfamilies, such as OATP1A, 
OATP1B, OATP1C etc., and the distinct OATPs within these subfamilies are 
assigned numbers based on when the proteins were identified.  Alternatively, if there 
is already an orthologue known, they are given the same number (12). The number of 
OATPs identified or predicted in protein databases now exceeds 300 from more than 
40 species (2), however there are only 11 OATPs known in humans, of which the four 
best characterised are expounded in this work: OATP1A2, OATP1B1, OATP1B3 and 
OATP2B1.  
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1.1.1.2 Structure and transport mechanism 
 
OATPs are sodium-independent transport systems that are predicted to have 12 
transmembrane regions, with a large extracellular loop between the 9
th
 and 10
th
 
domains containing several conserved cysteine residues (13). Due to the challenges 
associated with crystallising membrane proteins (14), their structures have not thus far 
been determined experimentally. To this date, the Rhesus glycoprotein ammonium 
transporter (SLC42A3) is the only human SLC with an experimentally defined crystal 
structure (15). X-ray crystal structures have been solved for proteins in the bacterial 
SLC13 and SLC28 superfamilies (16,17), however no OATP homologues have been 
found in bacteria or yeast suggesting that OATPs are specific to the animal kingdom 
(2). Hence, alternative methods of protein structure elucidation are needed.  
 
The implementation of comparative modelling based on crystal structures that have 
been solved for membrane transporters in the MFS has allowed the development of 
potential three-dimensional models for OATPs, including OATP1B1 (Figure 1.1) 
(18), OATP1B3 and OATP2B1 (19). Experiments utilising site-directed mutagenesis 
have been able to speculate the substrate binding sites of OATPs (20-22). 
Nevertheless, until it is possible to purify and crystallise an OATP, the mechanism by 
which OATPs transport substrates cannot be not fully understood.  
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Figure 1.1 Predicted topological model of human OATP1B1 with 12 transmembrane 
regions (18). Amino acids conserved in 77 out of 97 mammalian OATPs are indicated 
in black. Conserved cysteine residues are given in grey. 
 
OATPs are believed to function as organic anion exchangers, as indicated by 
experiments with reduced glutathione, glutathione conjugates and bicarbonate acting 
as counterions in rat OATP-mediated uptake of endogenous substrates (23-25). The 
mechanism of transport appears to be electroneutral and operates by coupling the 
cellular uptake of substrates with the efflux of intracellular compounds (26,27). A low 
extracellular pH such as that found in the duodenum, compared with the lower part of 
the intestine, has been observed to enhance uptake by various OATPs including 
OATP2B1 (2). This transporter is localised at the apical membrane of human 
enterocytes, among other epithelia, and substrates of OATP2B1 such as pravastatin 
have been shown to be preferentially absorbed from the duodenum (28).  
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Furthermore, modulation of OATP-mediated transport of substrates by other 
endogenous substrates has also been demonstrated, such as in the stimulation of 
OATP2B1-mediated uptake of estrone-3-sulfate by prostaglandins A1 and A2 (29). It 
has been suggested that no general transport mechanism exists for OATPs and that 
they have more than one substrate binding site, which may or may not interact (2). 
The second point has been made evident by the observation of biphasic kinetic 
behaviour in OATP1B1-mediated uptake of estrone-3-sulfate, indicating that there are 
distinct high and low affinity components on OATP1B1 for this substrate (30,31). 
 
In reviewing the current literature on OATPs, it is manifest that further research is 
required to explain their method of transport, as it may vary for different substrates in 
the same transporter. Likewise, depending on the transport mechanism, OATPs may 
or may not be able to concentrate a substrate within cells over the respective 
extracellular concentration, such as drugs in liver cells (2). While the knowledge on 
OATP transport mechanisms is incomplete, it is important to note that prototypical 
substrates and binding affinities of these substrates have been identified for the four 
key OATPs, including estrone-3-sulfate for OATP1A2, OATP1B1 and OATP2B1 
(32,33), and cholecystokinin octapeptide (CCK-8) for OATP1B3 (34). Cellular uptake 
assays using these substrates, which possess relatively high affinities for their 
respective transporters, have allowed the straightforward in vitro identification of 
transporter inhibitors, which may be substrates competing for translocation across the 
cell membrane or inhibitors at the substrate binding site(s) (27). Numerous drug 
substrates and inhibitors of solute carriers have already been demonstrated (Table 
1.1), which may alter the pharmacokinetics and toxicities of drugs utilising these 
transporters for uptake. 
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1.1.1.3 Tissue distribution 
 
Transporter 
(human gene 
symbol) 
Endogenous 
substrates 
Prototypical 
substrate 
Anticancer drug 
substrates 
Predominant 
tissue 
distribution 
 
OATP1A2 
(SLCO1A2)  
 
Taurocholate, bile 
salts, organic anions 
and cations (2) 
 
Estrone-3-sulfate 
(32) 
 
Hydroxyurea, imatinib, 
methotrexate (39-41) 
 
Brain, testis, 
kidney, intestine, 
liver, eye (2,4) 
 
OATP1B1 
(SLCO1B1) 
 
Bile salts, organic 
anions (2) 
Estrone-3-sulfate 
(33) 
Hydroxyurea, metho-
trexate, paclitaxel, SN-
38, sorafenib (39,42-
45) 
 
Liver (4) 
OATP1B3 
(SLCO1B3) 
 
 
Bile salts, organic 
anions (2) 
CCK-8 (34) Docetaxel, hydroxy-
urea, imatinib, metho-
trexate, paclitaxel,   
SN-38 (39,40,46-49) 
 
Liver (4) 
OATP2B1 
(SLCO2B1) 
 
Estrone-3-sulfate, 
DHEAS (2) 
 
Estrone-3-sulfate 
(33) 
N/A Liver, intestine, 
brain (2,27) 
OAT1 
(SLC22A6) 
Medium-chain fatty 
acids, prostaglandins 
E2 and F2 (3) 
 
p-aminohippuric 
acid (36) 
 
Mesna, methotrexate 
(50,51) 
Kidney, placenta, 
brain (3) 
 
OAT2 
(SLC22A7) 
Glutamate, 
prostaglandins E2 
and F2 (3) 
 
Estrone-3-sulfate 
(3) 
Docetaxel, fluorouracil, 
methotrexate, 
paclitaxel (52-54) 
Liver, kidney (3) 
OAT3 
(SLC22A8) 
cAMP, cortisol, 
prostaglandins E2 
and F2 (3) 
 
Estrone-3-sulfate 
(3) 
Erlotinib, 6-mercapto-
purine, methotrexate, 
topotecan (55-59) 
 
Kidney, brain, 
skeletal muscle 
(3) 
OAT4 
(SLC22A11) 
Estrone-3-sulfate, 
prostaglandins E2 
and F2 (3) 
 
Estrone-3-sulfate 
(3) 
Mesna, methotrexate 
(50,60) 
Kidney, placenta 
(3) 
OCT1 
(SLC22A1) 
Putrescine, 
salsolinol, agmatine 
(3) 
MPP
+ 
(37) Cisplatin, imatinib, 
oxaliplatin, picoplatin 
(40,61-65) 
Liver, intestine, 
kidney, lung, 
skeletal muscle, 
brain (3) 
 
OCT2 
(SLC22A2) 
Acetylcholine, 
dopamine, 
epinephrine, 
histamine (3) 
 
MPP
+ 
(37) Cisplatin, erlotinib, 
ifosfamide, oxaliplatin, 
picoplatin (55,61,65-
67) 
Kidney, intestine, 
lung, placenta, 
thymus, brain, 
inner ear (3) 
OCT3 
(SLC22A3) 
Epinephrine, 
histamine (3) 
MPP
+
 (38) Oxaliplatin (61) 
 
 
Broad (3,35) 
OCTN1 
(SLC22A4) 
Acetylcholine, 
ergothioneine, L-
carnitine (3) 
 
L-ergothioneine 
(3) 
Doxorubicin, 
mitoxantrone (68) 
Broad (3,35) 
OCTN2 
(SLC22A5) 
L-carnitine, choline 
(3) 
L-carnitine (3) Etoposide, imatinib 
(40,69) 
Broad (3,35) 
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Table 1.1 Synopsis of some of the endogenous, prototypical and known anticancer 
drug substrates of the 13 solute carriers discussed in this text and the tissues in which 
these transporters are predominantly found (2,3,4,27,32-69). Abbreviation: N/A, not 
available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Diagram of major drug transporters in various tissues (referenced from 
(27) with appropriate modifications). Essential drug transporters in the intestine (A), 
liver (B), kidney (C), and brain (D) are shown. Arrows illustrate the direction of 
substrate transport for each transporter. Circles coloured in blue represent uptake 
(A) Intestinal epithelia (B) Hepatocytes 
(C) Kidney proximal tubules (D) Blood-brain barrier 
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transporters in the SLCO and SLC22 superfamilies and are described in detail in this 
thesis. Circles coloured in red denote efflux transport proteins that are of importance 
but are not the topic of this thesis. *OATP1A2 is contrarily expressed in the distal 
tubules of the nephrons.  
 
OATPs are expressed in a variety of different tissues, in particular the intestine, liver, 
kidney and brain (Figure 1.2), which is indicative of their critical role in drug 
disposition (70). OATP1A2 has been detected at the apical (luminal) membranes of 
brain capillary endothelial cells (71), where it is believed to be part of the blood-brain 
barrier, and enterocytes (72), where it may mediate the uptake of exogenous 
compounds. Within the liver, OATP1A2 has limited expression at the basolateral 
(sinusoidal) membrane of hepatocytes (73), and is specifically localised to the apical 
membrane of cholangiocytes (74), where it may be involved in the reabsorption of 
drugs or xenobiotics excreted into the bile. This protein is also expressed at the 
luminal membrane of distal tubules of the nephrons, suggesting OATP1A2 may have 
an important role in the reabsorption of drugs that are filtered at the level of the renal 
proximal tubule (74). Additionally, it could be responsible for the secretion of 
exogenous compounds into urine (5). 
 
Whereas most OATPs are prevalent in multiple tissues, OATP1B1 and OATP1B3 are 
predominantly, if not exclusively, localised to the sinusoidal membrane of liver cells, 
hence they are considered to be of particular importance for hepatic drug elimination 
(75). There is extensive research into the functional characterisation of 
polymorphisms in the genes encoding these proteins and drug-drug interactions 
involving substrates of these hepatic transporters, such that OATP1B1 and OATP1B3 
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are both recommended in the European Medicines Agency (EMA) guideline and the 
United States Food and Drug Administration (FDA) draft guidance for drug 
interaction studies (76,77). 
 
While OATP2B1 is also found most abundantly on the basolateral membrane of liver 
tissue, it is expressed more ubiquitously throughout the body (78), for example at the 
apical membrane of brain capillary endothelial cells and the basal surface of the 
syncytiotrophoblast layer of placenta (71,79). OATP2B1 is additionally localised to 
the apical membrane of enterocytes (28), therefore it is possible that this transporter 
contributes to the absorption of its substrates from the intestinal lumen (80). 
 
1.1.1.3.1 Modulated tissue distribution in cancer 
 
Besides their expression in normal tissues, it is significant to note that several studies 
have shown altered tissue distribution of OATP proteins in some malignant tissues. 
For example, OATP1A2 has been detected in healthy colon tissue, yet this expression 
was markedly downregulated in colon cancer tissue (81). In the brain, OATP1A2 was 
localised to endothelial cells at the blood-brain and blood-tumour barriers, but not in 
glioma cells (71). Conversely in malignant breast cancer cells, such as the T47-D cell 
line derived from human breast ductal carcinoma and the hormone-dependent MCF-7 
cell line, OATP1A2 expression was significantly upregulated compared with normal 
breast epithelial cells (82). OATP1A2 is a known transporter of the hormone 
precursor estrone-3-sulfate, which when exposed to estrogen-dependent breast cancer 
cells has been demonstrated to cause increased cellular proliferation in vitro (83,84). 
Modulation of OATP1A2-mediated estrone-3-sulfate uptake in these cells through 
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concomitant treatment with an inhibitor or competing substrate may result in 
suppressed cell proliferation (85). Hence, OATP1A2 could be pursued as a novel 
therapeutic target for breast cancer treatment, along with other SLCs which are highly 
expressed in breast cancer tissue and transport estrone-3-sulfate (see Table 1.1). 
 
The liver-specific transporters OATP1B1 and OATP1B3 both appear to have 
decreased expression in hepatocellular carcinoma (HCC) (86,87), however 
interestingly these proteins are also expressed ectopically in several other cancer 
tissues (47). In contrast to OATP1A2, OATP1B1 levels were significantly enhanced 
in colon cancer tissue compared with normal colon tissue (81), whereas OATP1B3 is 
generally upregulated in a wide range of cancer types (11). Northern blot analysis has 
indicated the expression of OATP1B3 in gastric, colon, pancreatic and gallbladder 
cancer cell lines and cancer tissues (47,88,89), while in non-small cell lung cancer 
(NSCLC), OATP1B3 mRNA expression was considerably increased as opposed to 
the non-malignant surrounding tissue (90). OATP1B3 was also detected in cells of 
invasive ductal breast carcinoma, where its immunoreactivity was inversely correlated 
with tumour size and associated with a decreased risk of cancer recurrence and 
improved prognosis (91). The upregulation of these normally liver-specific proteins in 
cancer tissues may underlie their potential value as diagnostic and prognostic markers 
to improve cancer therapy. Additionally, OATP1B1 and OATP1B3 could serve as 
promising therapeutic targets given that they have been shown to transport several 
antineoplastic drugs, including the active irinotecan metabolite SN-38 (45,49), and 
paclitaxel (43,48). On the other hand, some anticancer drugs are inhibitors of these 
transporters, for example the tyrosine kinase inhibitor (TKI) lapatinib reduces 
OATP1B1-mediated uptake of the model substrate estradiol 17β-D-glucuronide (92). 
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OATP1B1 also shows high transport activity for estrone-3-sulfate and is upregulated 
in breast cancer cell lines (33,93), thus inhibition of OATP1B1-mediated uptake of 
this proliferation-inducing substrate into tumour cells may suggest a supplementary 
effect of treating breast cancer with lapatinib.  
 
Broadly expressed OATP2B1 has exhibited upregulation in the colon adenocarcinoma 
cell line CX-1 and several breast cancer cells lines (33,93). In breast cancer patients, 
expression of OATP2B1 was demonstrated to be positively correlated with tumour 
grade (94). Conversely, recent clinical data have shown OATP2B1 expression to be 
decreased in malignant breast tumours compared with non-malignant tissue samples 
(95). With respect to the latter study, the authors considered that their findings were 
due to the high interpatient variability in the expression levels of OATPs as opposed 
to the effect of cancer. In terms of OATP2B1 downregulation in malignant tissues, 
expression of this transporter appeared to be decreased in osteocarcinoma tissues 
compared with non-malignant aneurysmal bone cysts (96). Similarly to OATP1A2, 
OATP2B1 was not detected in glioma cells, but was expressed at endothelium of the 
blood-brain and blood-tumour barriers in the brain (71). 
 
1.1.1.4 Physiological role  
 
OATPs transport a wide range of structurally unrelated compounds, such as 
endogenous bile salts, bilirubin glucuronides and steroid hormone metabolites (2), and 
xenobiotics, including some anticancer drugs (see Table 1.1), HMG-CoA reductase 
inhibitors (statins), and plant compounds (97,98). The majority of OATP substrates 
are anionic amphipathic molecules with a relatively high molecular weight (more than 
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350 Da) and a high degree of albumin binding under physiological conditions (12), 
though OATP1A2 has also been demonstrated to transport bulky type II organic 
cations such as N-methyl-quinine (99). The four OATPs of interest in this thesis share 
similar substrate specificities (100); in particular the high degree of amino acid 
similarity between OATP1B1 and OATP1B3 (80% sequence identity) gives rise to 
their substantially overlapping substrate spectrum (42,101). The cellular influx of the 
anticancer drugs methotrexate and hydroxyurea are mediated by OATP1A2, 
OATP1B1 and OATP1B3 (39,41,42,47), while estrone-3-sulfate is transported by 
OATP1A2, OATP1B1 and OATP2B1. Both OATP1A2 and OATP1B3 are involved 
in the uptake of the TKI imatinib (40), and all statins in clinical use are substrates of 
OATP1B1 and OATP1B3 (42,100,102). OATP2B1 also contributes to the disposition 
of statins (103), however despite its broad substrate selectivity, OATP2B1 is the only 
SLC discussed in this work that has not yet been shown to transport anticancer agents 
(104,105).  Although OATP1B3 shares many substrates with OATP1B1 (5), it does 
selectively mediate the uptake of some compounds, for example the gastrointestinal 
peptide CCK-8 and the antihypertensive drug telmisartan (106,107). 
 
OATPs form part of a network of proteins involved in the disposition of substrates 
that includes phase I and II metabolic enzymes, such as cytochrome P450 (CYP) 
enzymes and glucuronosyltransferases respectively, and efflux transporters for 
example P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (see 
Figure 1.2) (105). The pharmacologic action of orally administered drugs is 
dependent on sufficient intestinal and hepatic absorption and distribution to sites of 
action, before their elimination by metabolic and excretory pathways (108). 
Regulation of OATPs at the transcriptional level, polymorphisms in the genes 
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encoding OATPs, and coadministration of inhibitors can lead to modulation of OATP 
activity (109), which may affect the bioavailability of drug substrates by hindering 
their absorption or facilitating their intracellular accumulation. The dynamic interplay 
between uptake and efflux transporters within epithelial cells is essential to our 
understanding of transporter-mediated drug disposition (108). 
 
1.1.1.5 Genetic polymorphisms and interindividual variations 
 
Extensive literature regarding the genetic variants of numerous drug transporters has 
been published (110-113), however, the impact of these variants on transport function 
and the scope of their contribution to interindividual variability of drug response 
requires further understanding. Recently, appropriate screening tools to investigate the 
functional consequence of large numbers of transporter single nucleotide 
polymorphisms (SNPs) in high-throughput assays have emerged (10,114).  
 
The first systematic analysis of the membrane transporters OATP1B1, OATP1B3, and 
OATP2B1 on the interindividual variability of hepatic expression revealed that 
expression of OATP1B1 is significantly affected by SLCO1B1 variants (115). The 
genetic variations in this transporter appear to be major contributors to drug 
disposition; for example several studies have shown that individuals carrying a loss-
of-function variant of OATP1B1 had increased area under the plasma concentration-
time curve (AUC) of pravastatin (see Figure 1.3) (113,116,117).  
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Figure 1.3 Representation of the influence of SLCO1B1 loss-of-function genetic 
variation on drug disposition (113). 
 
Expression of OATP1B3 or OATP2B1 is apparently not influenced by genetic 
variants, indicating that unidentified transcription factors, genetic variation in those 
genes, together with epigenetics such as DNA methylation or regulation by 
microRNA, may affect the interindividual variability of these transporters (115). 
Protein-altering variants of OATP1A2 potentially play a central role in interindividual 
variation in drug disposition and toxicity (41). Methotrexate and imatinib are two 
important anticancer drugs that have been determined as OATP1A2 substrates. 
Considering methotrexate therapy can result in severe toxicity in organs where 
OATP1A2 is expressed, including the kidney, liver, gastrointestinal tract and brain, 
clinical studies of OATP1A2 genetic variants are important to determine their 
(A)  
(B)  
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contribution to methotrexate therapeutic outcomes (41). It has recently been shown 
that polymorphisms in OATP1A2 and OATP1B3 are related to clearance of the 
imatinib (118,119), while a genetic variant of OATP2B1 has been associated with 
reduced bioavailability of the antihistamine fexofenadine (120). 
 
1.1.1.6 Drug-drug interactions 
 
Over the past decades, drug-drug interactions that inhibit intracellular drug 
metabolising enzymes, such as CYP enzymes, have been extensively studied, 
however knowledge of interactions inhibiting membrane transport proteins is still 
relatively limited (121). Many changes in the pharmacokinetics of drugs that cannot 
be explained by interactions at the metabolising enzyme level may be mediated by 
transporters (122). Some of the known inhibitors of the OATPs discussed in this 
thesis are summarised in Table 1.2 and include the antibiotic rifampicin and the 
grapefruit juice flavonoid naringin (123,124). Modulation of transport function by 
inhibitors may affect drug excretion pathways by suppressing OATPs involved in 
hepatobiliary elimination, in particular OATP1B1, OATP1B3 and OATP2B1 (125), 
thereby altering the plasma concentrations of a given drug substrate. In one study in 
healthy volunteers, it was shown that a single dose of rifampicin raised the AUC of 
coadministered atorvastatin by approximately seven-fold (126), probably by 
inhibiting OATP-mediated hepatic uptake of atorvastatin (100). The pharmacokinetics 
of drugs absorbed by OATPs from the intestine are potentially subject to interactions 
with other orally administered drugs and food; for example the immunosuppressant 
cyclosporine and green tea catechins have been demonstrated to inhibit the enteric 
transporters OATP1A2 and OATP2B1 (127-129). This may lead to a reduction in the 
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AUC or maximum systemic plasma concentration (Cmax,sys) of oral drug substrates of 
these transporters. Interestingly, inhibition studies have shown that compounds can 
have stimulatory, inhibitory or no effect on OATP-mediated transport, depending on 
the model substrate used, therefore study design in transporter-mediated drug-drug 
interaction experiments is important (2). 
 
1.1.1.7 Chemotherapeutic aspects 
 
During tumour progression cells acquire an altered metabolism, which may be due to, 
or as a result of, an increased demand for energy and nutrients (130). The 
upregulation of some OATPs in tumour cells as a consequence of these changed 
needs may be of therapeutic value. For example modulating transporter activity can 
influence the biological processes required for tumour growth (130), particularly in 
hormone-related cancers (131), since OATPs mediate the uptake of steroid hormone 
precursors such as estrone-3-sulfate. A novel approach to drug design would be to 
modify pharmaceuticals so they become substrates of OATPs, which may help to 
increase their uptake into OATP-expressing cancer cells (11,132). Several anticancer 
drugs substrates of OATPs have already been identified, including such structurally 
diverse compounds as imatinib, methotrexate, paclitaxel, the potent irinotecan 
metabolite SN-38 and hydroxyurea (Figure 1.4) (39-49). In humanised transgenic 
mice, OATP1B1, OATP1B3, and possibly OATP1A2 have been shown to influence 
the pharmacokinetic behaviour of two of these substrates: the polar anion, 
methotrexate; and the uncharged, highly lipophilic compound, paclitaxel (133). It is 
therefore anticipated that many drugs with intermediate physicochemical properties in 
the broad spectrum of shared OATP substrates will be similarly affected (133). 
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Figure 1.4 Selected anticancer drugs as substrates for organic anion transporting 
polypeptides (schematic cited from (105) with slight modification).  
 
Aside from mediating tissue distribution and elimination processes, these transport 
proteins provide intracellular drug concentrations necessary to reach a cytotoxic effect 
in cancer cells (105). This is inferred because there are anticancer drugs which 
accumulate in particular organs causing tissue-specific toxicity, but these adverse 
drug reactions can be modified by coadministration with chemical inhibitors of SLCs 
(134). Screening tumours for transporter expression prior to therapy with potential 
substrates could lead to SLC-targeted therapy with higher efficacy and decreased side 
effects (105). In considering SLC substrates or inhibitors for chemotherapy, it must 
also be conceded that suppressing these transporters therapeutically may interfere 
with normal physiological processes in the liver and impair the excretion of bilirubin, 
bile acids, drugs, and toxins (105).  
18 
 
 
1.1.2 Transporters in the SLC22 superfamily: OCTs, OCTNs and OATs 
 
In the years since the first member of the SLC22 family was identified and 
characterised (OCT1) (135), substantial progress has been made in identifying 
substrates and inhibitors of these transport proteins, as well as in defining genetic 
variants with altered expression or function (10). The current focus is on the 
elucidation of their three-dimensional structure, to allow for the prediction of drug-
related pathologies and the design of drugs targeted to individual SLCs (5).  
 
 
1.1.2.1 Nomenclature 
 
Members of the SLC22 family are predicted to adopt the structural fold associated 
with proteins in the MFS (136), in which they are assigned to subclass 2.A.1 
(uniporters, symporters, antiporters) according to the Milton Saier transporter 
classification system (137,138). The SLC22 family comprises three subgroups of 
transporters with closely related primary structures: OCTs, OCTNs and OATs (3). 
Three OCTs (OCT1-3, SLC22A1-3), two OCTNs (OCTN1 and OCTN2, SLC22A4-5), 
and four of the OATs (OAT1-4, SLC22A6-8, 11) found in humans are researched in 
this thesis. Most of these proteins have a single rodent orthologue, but OAT4 is 
specific to humans (5).  
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1.1.2.2 Structure and transport mechanism 
 
The SLC22 transporters all have a similar putative membrane topology consisting of 
12 α-helical transmembrane domains (TMDs), a large extracellular loop between 
TMDs 1 and 2 and a large intracellular loop between TMDs 6 and 7 (see Figure 1.5) 
(3). The MFS fold has been associated with a wide array of substrates, which can be 
explained partly by its large pore and extensive conformational movements during 
transport (136). Hence, like the SLCO transporters, the majority of SLC22 family 
members are polyspecific for substrates. SLC transporters mediate the influx of 
nutrients and substances essential for cell survival, such as sugars, digested peptides, 
amino acids, nucleosides, and inorganic ions (139), though numerous drugs have been 
found that ‘hitchhike’ on these transport proteins (140), and several additional 
compounds can act as high or low affinity inhibitors (141,142). 
 
 
 
Figure 1.5 Predicted membrane topology of a structural model of rat OCT1 (143).  
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Transporters within each subgroup tend to have similar transport mechanisms and 
substrate specificities (3).  For example, all members of the OCT subgroup translocate 
organic cations, weak bases and some neutral compounds (141,144,145). The OCTs 
are facilitative diffusion systems that transport organic cations in both directions 
across the plasma membrane, where the impetus is supplied by the electrochemical 
gradient of the transported compounds (3,146). 1-methyl-4-phenylpyridinium (MPP
+
) 
is a model cation that is transported by OCT1-3 and exhibits high maximal uptake 
rates (37,38,141).  
 
OCTN1 can act as a uniporter, such as in the transport of the zwitterionic antioxidant 
L-ergothioneine (147), while also mediating H
+
/organic cation antiport (141). OCTN2 
is also involved in the uniport translocation of organic cations, and mediates Na
+
/L-
carnitine co-transport (141). The relatively high binding affinity of OCTN1 and 
OCTN2 for L-ergothioneine and L-carnitine respectively (147,148), means that these 
compounds are useful as representative substrates in cellular uptake inhibition studies.  
 
Members of the OAT subgroup of transporters are able to transport anions in either 
direction across cell membranes by exchanging extracellular against intracellular 
organic anions (3). The concentration of the intracellular counterpart anion, which for 
OAT1-4 is a divalent organic anion such as succinate or α-ketoglutarate, must be 
higher in the cytosol than outside the cell in order to stimulate the ‘uphill’ uptake of 
organic anions through OATs (149). This concentration gradient is maintained by 
sodium-coupled anion transporters localised to the same membrane as the respective 
OAT (149). Para-aminohippuric acid (PAH) is a prototypical substrate for OAT1 
(36), while estrone-3-sulfate is a useful model substrate for OAT2-4 (3,150). 
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1.1.2.3 Tissue distribution 
 
In the kidney, OAT1, OAT2, OAT3, OCT2, and OCT3 assist in the movement of 
organic anions from blood across the basolateral membrane into the proximal tubule 
cells (38,151-154). OAT4, OCTN1, and OCTN2 are expressed at the apical 
membrane of these cells (155-159), and may be involved in the reabsorption from, or 
the secretion of xenobiotics into, urine. OAT2 and OCT1 are responsible for the 
uptake of drugs into the liver at the sinusoidal membrane of hepatocytes, along with 
the previously discussed OATPs (160-162). In enterocytes, OCT3 was found to be 
localised to the luminal membrane (163), along with OCTN1 and OCTN2 (164), 
where it may mediate the uptake of orally administered drugs and other exogenous 
compounds from the intestine. OCT1 and OCT2 were found to be expressed at the 
basolateral membrane of enterocytes (141,165), which is indicative of their role in 
uptake and elimination. A pictorial representation of SLC22 localisation in these three 
major organs of drug disposition, as well as the brain, is shown in Figure 1.2. 
 
1.1.2.3.1 Modulated tissue distribution in cancer 
 
The variability in OCT1 expression is influenced by genetic and epigenetic factors 
including altered expression during diseases. OCT1 has been detected in several 
human cancer cell lines, suggesting that this transporter may be expressed in the 
corresponding tumours (64,166). OCT1 expression is a major determinant of the 
activity of oxaliplatin, a known OCT anticancer substrate, and the observed 
upregulation of this transporter in human colon cancer cell lines may serve as a 
prognostic factor in colorectal cancer (64). Furthermore, DNA methylation of the 
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SLC22A1 gene is associated with the downregulation of OCT1 in HCC (167), which 
is subsequently related to advanced tumour stages and a worse patient survival (168). 
Increasing evidence suggests that OCT1 activity influences therapeutic outcome in 
patients with chronic myeloid leukaemia (CML) receiving imatinib therapy (143,169). 
For example, most CML patients with low OCT1 activity were found to have a 
suboptimal response to treatment with imatinib (170). However, in this study OCT1 
mRNA expression was not a strong predictor of clinical efficacy despite being 
correlated with OCT1 activity. This implies that OCT1 expression could merely be an 
indirect marker of imatinib transport or cellular accumulation and further study is 
required to interpret its clinical relevance (6). 
 
 
Expression profiling studies in the NCI-60 panel of cell lines determined that OCT2 
was distinctly upregulated in ovarian cancer cell lines, though tumour samples 
obtained from patients with ovarian cancer had low or absent OCT2 expression and 
no correlation between expression and clinical outcome was reported (67). Higher 
expression of OCT2 has been shown to increase cellular sensitivity to the anticancer 
drugs tetraplatin, and transplatin (67). OCT2 was found to be upregulated in colon 
cancer cell lines, (64) thus expression of this transporter may determine the efficacy 
of platinum-based therapy in colorectal tumours.  
 
OCT3 has been suggested as an suitable candidate for individualised kidney tumour 
therapy, because the sensitivity of some human renal carcinoma (RCC) cell lines to 
several important chemotherapeutics is dependent on the expression of OCT3 
(139,171). Real time PCR has shown a downregulation of the SLC22A3 gene 
encoding OCT3 in HCC compared to corresponding non-neoplastic tumour 
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surrounding tissue (168), however there was no significant difference in tumour 
characteristics due to OCT3 expression levels (168).  
 
High levels of OCTN1 and OCTN2 mRNA expression have been reported in some 
human tumour-derived cell lines (157,158), though the relevance of this upregulation 
to tumour growth has not been determined. In OCTN2-transfected human embryonic 
kidney 293 (HEK293) cells, imatinib uptake was increased compared with cells 
expressing OCT1, indicating that OCTN2 expression or function may be a 
determinant of clinical efficacy in imatinib therapy (40). 
 
An investigation of the NCI-60 panel revealed that OAT1, OAT2 and OAT3 mRNAs 
were not detected in any of the 60 cancer cell lines, though they were found to be 
expressed in kidney (OAT1-3) and liver (OAT2) mRNA samples (68), consistent with 
previous findings (152,153,160). Interestingly, elevated hepatocellular expression of 
OAT2 after castration in prostate cancer patients has been linked with an increased 
hepatic uptake of docetaxel and hence a decrease in systemic exposure of this OAT2 
substrate (52), suggesting that dose escalation may benefit castrated patients. 
 
1.1.2.4 Physiological role  
 
SLC22 transporters function in a coordinated manner with each other, as well as other 
proteins including receptors, enzymes and efflux transporters, in various major 
biological and pharmacological processes. OCT1 regulates the first step in hepatic 
excretion of many cationic drugs and xenobiotics, by mediating their uptake across 
the sinusoidal membrane into the hepatocyte (3). OCT2 mediates the first step in renal 
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excretion of many organic drugs, for example, the antineoplastic drug oxaliplatin (3). 
OCT3 is involved in the uptake of organic cations into brain, heart, and liver and 
participates in their biliary excretion (3). OCTN1 is important for the absorption of 
ergothioneine in the small intestine and for its reabsorption in renal proximal tubules, 
while OCTN2 mediates the uptake of L-carnitine by enterocytes and its reabsorption 
in the kidney. OAT1 and OAT2 regulate the renal excretion of urate, and the 
reabsorption of endogenous and exogenous anions (3). In liver, OAT2 mediates the 
efflux of glutamate into the sinusoids and the uptake of various endogenous 
compounds, drugs and toxins into hepatocytes (3). In the kidney, OAT3 transports 
organic anions across the basolateral membrane of proximal tubules for renal 
secretion by apical transporters (151), such as OAT4. OAT4 also contributes to the 
reabsorption of filtered urate, prostaglandins, anionic drugs and xenobiotics (3). 
OAT4 is hypothesised to be important for the uptake of dehydroepiandrosterone 
(DHEAS) by the placenta in order to prevent intrauterine growth retardation caused 
by excess DHEAS (172).  
 
1.1.2.5 Genetic polymorphisms and interindividual variations 
 
Genetic variations in membrane transporters may contribute to the interindividual 
variability in the efficacy and safety of therapeutics, including cancer chemotherapy. 
Although uptake carriers have been extensively genetically characterised, relevant 
pharmacogenetic data are still very limited (10). Genetic variants of uptake 
transporters have predominantly been investigated for OATPs, however more recently 
a number of SNPs in the OCT (SLC22A1-3) genes were found to alter transport 
function and substrate selectivity in vitro (144). OCT1 has 18 SNPs that modify 
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amino acids; six have reduced transport activity and one has increased activity (173). 
The pharmacokinetics of imatinib and the antidiabetic drug metformin are 
significantly affected by OCT1 variants (174,175). OCT2 has ten genetic variants, all 
of which are functionally active (141), though variants of this transporter have also 
been shown to alter the transport kinetics of metformin (176), suggesting that OCT2 
mutations may contribute to the interindividual variability in metformin disposition 
(177). Five SNPs have been identified in OCT3, three of which show reduced 
transport activity (178), while a novel susceptible locus in SLC22A3 encoding this 
transporter was reported to contribute to the risk of distal colon cancer in an Asian 
population (179). Mutations in the gene cluster that contains the OCTN1 and OCTN2 
genes have been associated with autoimmune diseases (180,181). Debilitating 
mutations in the OCTN2 gene have been shown to cause systemic carnitine 
deficiency, which results from a lack of L-carnitine reabsorption in the kidney (182). 
In a retrospective study looking at patients treated with imatinib for gastrointestinal 
stromal tumour (GIST), polymorphisms were identified in the imatinib transporter 
genes SLC22A4 (OCTN1) and SLC22A5 (OCTN2) that improved time to progression 
(183). Genetic variants for the OATs are less well-characterised, though several have 
been found which affect transport function (151). 
 
1.1.2.6 Drug-drug interactions 
 
As with the OATPs, an important risk of pathology associated with members of the 
SLC22 family is that of adverse drug-drug interactions (5). Oxaliplatin was found to 
be a substrate of the OCTs, which are believed to play a role in its anticancer effects 
by facilitating oxaliplatin entry into tumour cells (64,184). The TKIs gefitinib, 
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erlotinib, nilotinib and sunitinib were shown to inhibit the uptake of metformin in 
cells overexpressing OCT proteins, and were hence evaluated for their drug-drug 
interaction potential with oxaliplatin (185). It was observed that the cellular uptake of 
platinum was reduced after oxaliplatin treatment in the presence of clinically relevant 
concentrations or erlotinib and nilotinib, suggesting that combination therapy 
involving oxaliplatin and these TKIs may not be optimal (185). Concomitant 
administration of the antigout drug probenecid and methotrexate was noted over 30 
years ago to result in prolonged systemic circulation of methotrexate (186). This can 
today be explained by the inhibition of OAT3- and OAT1-mediated methotrexate 
transport by probenecid (187). Given that erlotinib has been determined as a substrate 
of OAT3 and OCT2 (55), cotreatment of this TKI with methotrexate or oxaliplatin 
may alter the pharmacokinetics of these drugs via transporter-mediated drug-drug 
interactions. Several other drug substrates and interactions of anticancer drugs with 
SLC22 proteins are listed in Tables 1.1 and 1.2.  
 
1.1.2.7 Chemotherapeutic aspects  
 
The modulated expression levels of SLC22 proteins in cancer have important 
consequences for an individual’s susceptibility to certain chemotherapy-induced side 
effects, drug-drug interactions, and treatment efficacy (6). Drug resistance, for 
instance, can be provoked by overexpression of efflux pumps or reduced expression 
of SLCs, whereas SLCs that are overexpressed in tumour cells may serve as 
chemosensitising targets (130). A novel treatment approach has recently been 
suggested which involves the chemically-induced enhancement of influx transporter 
expression in tumour cells. This results in the accumulation of anticancer substrates 
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within these sites, which may lead to an increased therapeutic window for 
chemotherapeutic agents (6,188).  
 
The expression of OCT1 in CML cells has been correlated with the therapeutic effect 
of imatinib (62), however, only minor or no OCT1-mediated transport of imatinib has 
been demonstrated (40). A potential explanation for this inconsistency is that 
endogenous OCT1 substrates influence the therapeutic effect of imatinib that enters 
the cells by OCT1-independent pathways (3). The intracellular toxicity of some 
platinum derivatives besides oxaliplatin, such as cisplatin and picoplatin, is markedly 
increased in OCT1- and OCT2-transfected cells, suggesting that they are also 
substrates of these transporters. OCTN1 mediates the cellular uptake of the anticancer 
drugs mitoxantrone and doxorubicin, thereby conferring cellular sensitivity to these 
agents (68). A list of the known anticancer drug substrates of SLC22 transporters can 
be found in Table 1.1. 
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1.2 Tyrosine kinase inhibitors 
 
 
Cancer is one of the most common causes of death globally and in Australia; in 2011 
around 30% of all deaths registered in this country were cancer-related (189). Over 
the past decades, mechanistic studies on tumour cell proliferation have led to a 
superior understanding of the processes that trigger cancer growth, such as the 
activation of tyrosine kinases (TKs), which in turn stimulate signal transduction 
cascades within cells. In most cancers, one or more signal transduction pathways are 
activated or mutated resulting in cell proliferation. The development of specific 
targeting drugs, for example small molecule tyrosine kinase inhibitors which impede 
predefined TKs involved in carcinogenesis, has revolutionised cancer research since 
1988 (190). Imatinib became the first TKI to be approved for cancer treatment in 
2001, which blocks cell growth and induces apoptosis by inhibiting the BCR-ABL 
kinase (191). In addition to this enzyme, the main targets of currently approved TKIs 
include: epidermal growth factor receptor (EGFR), platelet-derived growth factor 
receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR) and human 
epidermal growth factor receptor (HER), among other TKs and some TK-like kinases.  
 
At present there are 21 orally available TKIs for the treatment of cancer (see Figure 
1.6), 10 of which were approved by the FDA in the last two years (192), emphasising 
the clinical importance of these drugs. Notable examples of diseases that were 
previously only treated with chemotherapy, for which effective TKIs now exist, 
include CML, GIST and RCC (193). While TKIs are typically better tolerated than 
the alternative, chiefly non-specific cytotoxic chemotherapeutics (194), they are 
associated with a number of serious toxicities and adverse events in some patients. 
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There is a high degree of interindividual variability in the pharmacokinetics of these 
drugs, which may be related to differential expression or function of drug 
metabolising enzymes or transporters for which TKIs are substrates. Furthermore, 
TKIs have been implicated in several drug-drug interactions which may significantly 
influence drug safety and efficacy. Information on the clinical relevance of their 
interaction potential and inhibitory effects on proteins, especially influx transporters, 
is lacking.  
 
1.2.1 Role of tyrosine kinases 
 
Most disease states emanate from signal transduction pathways which have gone awry 
(195). Signal transduction is essential for proper cell function, as it regulates gene 
expression and ultimately protein synthesis (196). The majority of extracellular 
signals are transmitted into cells via the receptor-ligand signalling pathway, which 
drives a series of downstream effects targeting the nucleus, where important processes 
such as cancer cell proliferation, apoptosis, angiogenesis and metastasis are 
modulated. Tyrosine kinases involved in this signal transduction cascade are 
frequently altered or upregulated in malignant tumours, rendering them ideal targets 
for highly selective cancer treatment (196). Tyrosine kinases can be classified as 
receptor TKs (RTKs) and nonreceptor TKs (NRTKs). RTKs are transmembrane 
proteins with a ligand-binding extracellular domain and a catalytic intracellular kinase 
domain, while nonreceptor TKs lack transmembrane domains and are found in the 
cytosol, the nucleus, and the inner surface of the plasma membrane (197). Both are 
associated with many types of cancer including NSCLC, breast cancer and medullary 
thyroid cancer. 
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Figure 1.6 21 FDA approved TKIs and their targets (image cited from (195) 
supplemented with current information).  
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1.2.2 Inhibitors of receptor tyrosine kinases 
 
RTKs consist of single transmembrane domains separating the intracellular kinase 
domains from extracellular domains. Ligand binding to the extracellular domain 
induces dimerisation of receptors, leading to activation of the kinase, usually by 
autophosphorylation on tyrosine residues (198). The precise reaction that TKs 
catalyse is the transfer of the γ-phosphate of adenosine triphosphate (ATP) to 
hydroxyl groups of tyrosine residues in signalling protein substrates (199), which 
initiates a cascade of cytoplasmic enzymatic reactions. RTKs can be dysregulated in 
cancer cells in several ways, for example they may be overexpressed (Figure 1.7), 
fused with partner proteins, or mutated.  
 
 
 
 
 
Figure 1.7 Overexpression of a normal receptor TK (EGFR) in cancer, leading to 
activation of the TK. Small molecule TK inhibitors (labelled in red) usually act to 
block binding of ATP or substrate to the catalytic (Cat) domain of the TK (197). 
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Thus far, the ATP binding site in the tyrosine kinase domain has proven to be the 
most susceptible target for inhibitory drugs and all of the TKIs discussed in this thesis 
bind to the ATP binding clefts of the relevant targeted TKs. ATP-competitive 
inhibitors exhibit a remarkable degree of specificity given the general sequence 
conservation in the ATP binding pocket of protein kinases (199).  
 
1.2.2.1 Inhibitors of the HER family 
 
EGFR and HER2 belong to the HER family of RTKs, which is characterised by the 
binding of EGF-like or neuregulin ligands to the extracellular domain (200). The 
kinase sites of these enzymes are around 80% identical, however selective inhibitors 
have been generated that distinguish between EGFR and HER2 (201), including some 
TKIs. Overexpression of EGFR is a molecular hallmark of many human malignancies 
(195), particularly epithelial cancers such as metaplastic breast cancer (202); 
similarly, amplification of the gene encoding HER2 is associated with advanced 
disease and poor prognosis in around 30% of breast tumour cases (203). Mutations in 
the genes encoding EGFR and HER2, resulting in aberrant expression and signalling, 
have been correlated with cancer of the lung, oesophagus, head and neck, ovary and 
pancreas, among other tissues (204,205). Accordingly, the possibility of targeting 
HER family kinases for cancer therapy has been the focus of much research. The first 
generation of TKIs which target this family include gefitinib and erlotinib, while 
lapatinib, afatinib, neratinib and pelitinib are second generation inhibitors (206-209). 
Lapatinib is regarded as second generation because it is usually administered after 
treatment of breast cancer with the monoclonal antibody trastuzumab in cases where 
the disease has progressed (210). 
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(A) 
 
 
(B) 
 
 
 
Figure 1.8 Chemical structures of first generation HER inhibitors: (A) gefitinib and 
(B) erlotinib. (A) depicts the quinazoline moiety common to several TKIs. 
 
TKIs of the 4-anilinoquinazoline class are rationally designed drugs to treat patients 
possessing tumours with defined genetic alterations of the HER TK domain. A 
number of groups independently reached the quinazoline scaffold, though Zeneca was 
the first to develop a clinically viable agent (gefitinib; Figure 1.8 (A)) (195). This was 
soon followed by erlotinib (Figure 1.8 (B)). Gefitinib is an orally active compound 
that selectively inhibits EGFR by blocking the ATP binding cleft in the intracellular 
kinase domain (211,212). Gefitinib is approved for the treatment of NSCLC. Erlotinib 
shares the 4-anilinoquinazoline framework with gefitinib, binds similarly to the ATP 
binding pocket of EGFR, and is also used to treat NSCLC (213). Furthermore, 
erlotinib is approved for the first-line treatment of metastatic pancreatic cancer (214). 
quinazoline 
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(C) 
 
(D) 
 
 
Figure 1.9 Chemical structures of second generation HER inhibitors: (A) lapatinib, 
(B) afatinib, (C) neratinib and (D) pelitinib. 
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Lapatinib is the third TKI to be developed with the 4-aniloquinazoline core, as seen in 
Figure 1.9 (A). It is a dual EGFR/HER2 inhibitor which blocks the ATP binding cleft 
resulting in reduced autophosphorylation on EGFR or HER2 tyrosine residues (213). 
Lapatinib is approved for HER2-positive and hormone receptor-positive metastatic 
breast cancer therapy (215). 
 
Despite the initial response to the first generation inhibitors gefitinib and erlotinib, the 
majority of patients will eventually develop resistance to these inhibitors and relapse 
after several months (216). Most cases of acquired resistance to gefitinib and erlotinib 
can be explained by specific secondary mutations in the EGFR kinase domain (217), 
therefore a new collection of TKIs have come into clinical development which target 
these altered TKs. 
 
Afatinib is a second generation, irreversible inhibitor of EGFR and HER2 derived 
from the quinazoline chemical series, as shown in Figure 1.9 (B) (208). Irreversible 
binding occurs via a cysteine residue within the ATP binding site, which is conserved 
in EGFR and HER2 (218). Afatinib was approved by the FDA in July 2013 as the 
first-line treatment of patients with NSCLC, whose tumours have EGFR exon 19 
deletions or exon 21 substitution mutations (219). 
 
The first irreversible HER family kinase inhibitor to reach advanced clinical trials was 
neratinib (HKI-272; Figure 1.9 (C)) (209). Like afatinib, this compound is predicted 
to covalently modify a cysteine residue within the ATP binding pocket of EGFR and 
HER2 kinase domains (220). Neratinib has been evaluated in phase II trials for the 
treatment of NSCLC in patients who are resistant to gefitinib and erlotinib (209), 
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however there are no ongoing trials for this disease. It is currently in phase III trials 
for the treatment of HER2-positive breast cancer, in which it has been shown to 
overcome acquired resistance to trastuzumab (221). Neratinib has activity against the 
HER4 kinase in addition to EGFR/HER2 (222), hence its classification as a ‘pan-
HER’ inhibitor. 
 
Pelitinib (EKB-569) is a second generation, potent irreversible inhibitor of EGFR and 
a moderately less effective irreversible inhibitor of HER2 (223). Pelitinib is believed 
to suppress the downstream signalling instigated by these kinases by forming a 
covalent bond to a conserved cysteine residue located in their respective ATP binding 
sites (223). This compound is in phase I clinical trials for the treatment of gefitinib-
resistant NSCLC patients (224). 
 
1.2.2.2 Multikinase inhibitors 
 
Multikinase inhibitors (MKIs) are compounds that inhibit multiple RTKs, for example 
PDGFRs, VEGFR1-3, and Raf kinases. MKIs have transformed anticancer therapy as 
they inhibit receptors involved in angiogenesis, the physiological process by which 
cells expand their vascular network, which is crucial for cancer cell survival (225). 
This type of targeted therapy has become the standard treatment for several tumour 
types, particularly solid tumours, such as metastatic RCC, NSCLC, GIST and 
colorectal cancer (226). One of the main angiogenic growth factors is VEGF, which 
binds to VEGFR1-3, causing ATP-mediated induction of the RTK. Activation of 
VEGFR mediates proliferation, vascular permeability, cell migration and cell 
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survival, leading to angiogenesis. Overexpression of VEGF and VEGFR has been 
reported for many clinically important solid cancers (227). 
 
The PDGFRs, comprising PDGFR-α and PDGFR-β, are RTKs that are activated by 
PDGFs, and are involved in differentiation and cell proliferation (228). Alterations in 
the activities of these receptors are associated with a range of human cancers. 
Erroneous expression of both PDGF ligands and the PDGFRs is believed to influence 
the development of high-grade sarcomas and glioma (229). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Structures of the MKI sorafenib and five of its metabolites (230). Solid 
and dotted arrows indicate major and minor metabolic pathways respectively. 
(M-3) (M-2) (M-4) 
(M-5) (M-1) 
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The MKI sorafenib targets several RTKs including VEGFR1-3, PDGFR-β, FMS-like 
tyrosine kinase 3 (Flt-3, coded by the protooncogene known as FMS) and stem cell 
factor receptor (c-Kit), in addition to the serine/threonine kinases B-Raf and C-Raf 
(231). This drug is approved for the treatment of advanced RCC, HCC and 
differentiated thyroid cancer (230,232). Several sorafenib metabolites have been 
identified in the plasma of treated patients (233), five of which are shown in Figure 
1.10. These compounds have also been found to suppress cell proliferation by 
inhibiting the ERK/MEK signalling cascade initiated by Raf kinase activation; in 
particular the M-4 metabolite N’-desmethylsorafenib decreased cell viability in the 
MDA-MB-231 cell line (230).  
 
(A) 
 
 
(B) 
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(C)  
 
 
(D) 
 
 
 
Figure 1.11 Chemical structures of multikinase inhibitors: (A) sunitinib, (B) 
vandetanib, (C) cediranib and (D) foretinib. 
 
Figure 1.11 (A) shows sunitinib, an inhibitor of VEGFR2, PDGFRs α and β, Flt-3 and 
c-Kit (234). It is approved for the treatment of metastatic RCC, imatinib-resistant 
GIST and progressive and well-differentiated pancreatic neuroendocrine tumours 
(235). In several tumour models, sunitinib monotherapy appeared to have the 
cumulative antitumour activity associated with combined single-target inhibitors, 
supporting the hypothesis that the use of multitargeted agents may allow for improved 
overall efficacy (236).  
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The MKI vandetanib is the first effective therapeutic agent against metastatic 
medullary thyroid cancer (237,238). This compound is a member of the quinazoline 
class of TKIs, as illustrated in Figure 1.11 (B). Vandetanib simultaneously targets 
EGFR, which induces proliferation, as well as Ret kinase, an RTK for the glial cell 
line-derived neurotrophic factor, which mediates survival and migration of tumour 
cells, and VEGFR2 in the endothelial compartment (195). Hence, it addresses three 
aspects of cancer: proliferation, survival, and invasion of both the tumour cell and its 
growing vascular network (195).  
 
Cediranib (AZD-2171) is another quinazoline derivative, as seen in Figure 1.11 (C), 
and is a highly selective potent inhibitor of VEGFR2, with moderate inhibition 
activity against VEGFRs 1 and 3, c-Kit and PDGFR-β (239). This compound has 
exhibited significant antitumour effect and acceptable toxicities in clinical trials of 
patients with advanced solid tumours (240,241), however its development in oncology 
has recently been halted owing to insufficient results in phase II trials for the 
treatment of NSCLC and HCC among other cancers (241). In 2012, cediranib was in 
phase III trials for the treatment of metastatic colorectal cancer in combination with 
an oxaliplatin-based regimen (FOLFOX or CAPOX), however the overall survival 
endpoint of this study was not met (242). Despite its discontinuation, there are 
ongoing studies investigating the antitumour activity of cediranib (243,244). 
 
Foretinib (GSK1363089) is an inhibitor of the RTKs VEGFR2 and c-Met (the 
receptor for hepatocyte growth factor) (245,246). Antitumour activity of this 
compound has been observed in papillary RCC, head and neck cancer, and metastatic 
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gastric cancer. Foretinib is currently undergoing phase II trials for the treatment of 
each of these diseases (247-249). 
 
1.2.3 Inhibitors of nonreceptor tyrosine kinases 
 
The nonreceptor TKs are maintained in an inactive state by cellular inhibitor proteins 
and lipids and through intramolecular autoinhibition (Figure 1.12) (197).  
  
 
 
Figure 1.12 Schematic of the nonreceptor TK BCR-ABL in its inactive state (197). 
PIP2, phosphatidylinositol 4,5-bisphosphate (an inhibitory membrane lipid); ATP, 
ATP binding domain; Cat, catalytic domain; Tyr, regulatory tyrosine residue; Pro, 
proline residue; SH, Src homology domain; Myr, N-terminal myristate (membrane 
association group). 
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NRTKs are critical components in the regulation of the immune system, for example 
in signalling by activated T and B cells (199). The prime example of a dysregulated 
NRTK in the hematologic cancers is BCR-ABL (199), which is invariably associated 
with CML (250). NRTKs are involved in signalling cascades triggered by RTKs and 
other cell surface receptors, which ultimately modulate cell proliferation and 
differentiation. They are activated by phosphorylation of tyrosine residues in their 
activation loop, which can occur via trans-autophosphorylation (i.e. between 
receptors) or phosphorylation by a different NRTK (199). 
 
(A) 
 
 
(B) 
 
 
Figure 1.13 Chemical structures of nonreceptor tyrosine kinase inhibitors: (A) 
nilotinib and (B) bosutinib. 
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Along with imatinib, which is not discussed further in this thesis, nilotinib and 
bosutinib are TKIs approved for the treatment of CML. In action they target the BCR-
ABL kinase which is involved in clonal expansion of leukemic cells by deregulation 
of cell proliferation (251).  
 
Nilotinib (Figure 1.13 (A)) was rationally designed based on the concept that the 
potency and selectivity of imatinib could be improved by maintaining binding to the 
inactive conformation of the BCR-ABL kinase domain (252). Nilotinib is also active 
against other targets, including c-Kit and PDGFRs α and β (252). Aside from CML, 
nilotinib is being considered for the treatment of GIST (253). 
 
Bosutinib, shown in Figure 1.13 (B), additionally inhibits another NRTK, Src kinase, 
overexpression of which is often linked to a migratory and invasive cancer cell 
phenotype (254). Upregulation of Src kinase has been detected in a number of cancer 
types, including prostate and colon (255,256). In addition to its use in CML patients, 
bosutinib is currently in phase I clinical trials for the treatment of various advanced 
solid tumours (257), and phase II trials for breast cancer therapy (258). 
 
The 13 TKIs heretofore described are investigated for their interaction potential with 
SLCs in the present research. 
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1.2.4 Interactions of TKIs with SLCs 
 
Despite the high lipophilicity of most TKIs, which is usually indicative of passive 
membrane permeation, most studies examining the interplay of TKIs with transporters 
in the SLCO and SLC22 families have focused on substrate rather than inhibition 
interactions (185). Table 1.2 presents the already known substrate and/or inhibitor 
interactions of TKIs with SLCs. 
 
OATP substrates are generally associated with having high molecular mass, low 
permeability and anionic, hydrophilic properties, for example statins (259). 
Regardless of this, several TKI substrates and inhibitors of OATPs have been 
determined. Erlotinib and lapatinib inhibit the transporters OATP2B1 and OATP1B1 
respectively, at potentially clinically relevant concentrations (92,260). Currently, there 
are no data on the impact of either of these TKIs on the pharmacokinetics of OATP 
substrates in humans (261). Sorafenib was shown to be transported by OATP1B1 and 
OATP1B3 (44), and may be a substrate of the other hepatic SLCO transporters, 
OATP1A2 and OATP2B1 (262). Gefitinib and nilotinib are also potential substrates 
of OATP1B1 and OATP1B3, while sunitinib and vandetanib may be substrates of 
OATP1B1 and OATP1B3 respectively (44). Conversely, uptake of nilotinib in 
OATP1A2-overexpressing cells showed no significant accumulation as compared 
with control cells (118). 
 
A positive net charge and high lipophilicity were found to be key physicochemical 
properties required for OCT inhibition (263); characteristics which several TKIs 
possess (185). In vitro experiments using transporter-overexpressing HEK293 cells 
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demonstrated that gefitinib is not a substrate of OCT1 and OCT2, however it does 
inhibit OCT1- and OCT2-mediated MPP
+
 uptake and OCT3-mediated metformin 
uptake (185,264). Erlotinib also inhibits OCT1 at potentially clinically relevant 
concentrations (185), and is a substrate of OCT2 (55). In contrast, lapatinib and 
sorafenib had little effects on the uptake of metformin by OCT1-3, while sunitinib 
was a potent inhibitor of all three OCTs (185). Recently, sorafenib has been 
determined as a substrate of OCT1 and downregulation of this transporter in HCC has 
been suggested to affect sorafenib uptake into tumour cells (262,265). Vandetanib 
was found to be a moderate inhibitor of OCT2-mediated MPP
+
 and metformin uptake 
(266). Nilotinib is not transported by OCT1 (63,267), though it does inhibit the uptake 
of tetraethylammonium (TEA) by this transporter (266), in addition to potently 
inhibiting OCT3-mediated metformin uptake in HEK293 cells (185). 
 
Sorafenib and sunitinib are the only TKIs thus far to be investigated in substrate 
interaction studies involving organic zwitterion/cation transporters, and no significant 
uptake of either compound was observed in cells overexpressing OCTN1 or OCTN2 
(234). 
 
The binding of substrates to OATs appears to be driven by hydrophobicity (268), 
suggesting that highly lipophilic TKIs have the potential to be substrates or inhibitors 
of these proteins. Erlotinib was found to be a substrate of OAT3 (55), while lapatinib 
is a moderate inhibitor of this transporter (92). Contrastingly, lapatinib had little 
effects on OATs 1, 2 or 4 (92). Sorafenib and sunitinib are not substrates of OAT2 or 
OAT3 (234), and vandetanib is not an inhibitor of OAT1 or OAT3 (265). 
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TKI 
 
Known pharmacokinetic interactions  
Transporter-TKI 
interactions 
Transporter 
inhibitors (non-TKI) 
    
Gefitinib 
 
 Gefitinib ↑ metoprolol AUC (269) 
 Itraconazole ↑ gefitinib AUC (269) 
 Ketoconazole ↑ gefitinib AUC (270) 
 Ranitidine ↓ gefitinib AUC (270) 
 Rifampicin ↓ gefitinib AUC (269) 
 Sorafenib ↑ gefitinib AUC (271) 
 May be substrate of 
OATP1B1 and 
OATP1B3 (44) 
 Inhibitor of OCT1-3 
(185,264) 
 Rifampicin inhibits 
OATP1B1 and 
OATP1B3 (123,272) 
 Ranitidine inhibits 
OCT1-3 (273) 
 
 
Erlotinib 
 
 
 Cigarette smoking ↓ erlotinib AUC 
(274) 
 Ketoconazole ↑ erlotinib AUC (274) 
 Phenytoin ↓ erlotinib AUC (275) 
 Rifampicin ↓ erlotinib AUC (274) 
 
 Substrate of OAT3 
and OCT2 (55) 
 Inhibitor of 
OATP2B1 (260) 
 Inhibitor of OCT1-3 
(185) 
 
 Probenecid and 
novobiocin inhibit 
OAT3 (27) 
 Ranitidine inhibits 
OCT1-3 (273) 
 Naringin (grapefruit) 
and rifampicin 
inhibit OATP2B1 
(123,124,272,277, 
278) 
    
Lapatinib 
 
 Carbamazepine ↓ lapatinib AUC 
(279) 
 Grapefruit ↑ lapatinib AUC (280) 
 Ketoconazole ↑ lapatinib AUC (279) 
 Lapatinib ↑ SN-38 AUC (281) 
 Paclitaxel ↑ lapatinib AUC (282) 
 Inhibitor of 
OATP1B1 and 
OAT3 (92) 
 Rifampicin inhibits 
OATP1B1 (272) 
 Probenecid and 
novobiocin inhibit 
OAT3 (27) 
    
Afatinib 
 
 Rifampicin ↓ afatinib AUC (219) 
 Ritonavir ↑ afatinib AUC (219) 
    N/A     N/A 
    
Neratinib 
 
 Ketoconazole ↑ neratinib exposure 
(283) 
    N/A     N/A 
    
Pelitinib     N/A     N/A     N/A 
 
Sorafenib 
 
 
 No effect of ketoconazole (284) 
 Neomycin ↓ sorafenib AUC (232) 
 Rifampicin ↓ sorafenib AUC (196) 
 Sorafenib ↑ doxorubicin AUC (285) 
 Sorafenib ↑ gefitinib AUC (271) 
 Sorafenib ↑ SN-38 AUC (285) 
 
 Substrate of 
OATP1B1 and 
OATP1B3 (44) 
 May be substrate of 
OATP1A2 and 
OATP2B1 (262) 
 Substrate of OCT1 
(265) 
 
 Rifampicin inhibits 
OATP1B1, 
OATP1B3, 
OATP1A2 and 
OATP2B1 (123,272) 
 Naringin (grapefruit) 
inhibits OATP1A2 
and OATP2B1 
(124,277,278,286)  
 Quinidine inhibits 
OCT1 (27) 
 
Sunitinib  Ketoconazole ↑ sunitinib AUC (287) 
 Rifampicin ↓ sunitinib AUC (288)  
 
 May be substrate of 
OATP1B1 (44) 
 Inhibitor of OCT1-3 
(185) 
 Rifampicin inhibits 
OATP1B1 (272) 
 Ranitidine inhibits 
OCT1-3 (273) 
    
Vandetanib 
 
 Itraconazole ↑ vandetanib AUC (289) 
 Rifampicin ↓ vandetanib AUC (290) 
 
 May be substrate of 
OATP1B3 (44) 
 Inhibitor of OCT2 
(266) 
 
 Rifampicin inhibits 
OATP1B3 (272) 
Ranitidine inhibits 
OCT2 (273) 
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Table 1.2 Pharmacokinetic consequences of TKIs coadministered with drugs/food and 
known interactions of TKIs and other compounds with SLCs. Abbreviations: N/A, not 
available; IUR, intracellular uptake and retention. 
 
No interactions of afatinib, neratinib, pelitinib, sorafenib metabolites, cediranib or 
bosutinib with SLC transporters are reported in the literature, however it has been 
determined that bosutinib is not an OCT1 substrate in unpublished work (298).  
 
1.2.5 Drug-drug pharmacokinetic interactions 
 
Cancer patients are often polymedicated, elderly and treated by different physicians 
who might not be in regular contact with each other, hence the risk of adverse drug 
reactions in this population is high (299). Drug-drug interactions can affect plasma 
drug monitoring, which is an important factor to optimise antitumour efficacy and to 
minimise drug toxicity towards normal tissues (300). Anticancer drugs also have a 
 
TKI  
 
Known pharmacokinetic interactions 
Transporter-TKI 
interactions 
Transporter 
inhibitors (non-TKI) 
    
Cediranib 
 
 Cediranib ↑ temozolomide AUC (291) 
 Ketoconazole ↑ cediranib AUC (292) 
 Rifampicin ↓ cediranib AUC (292) 
   N/A     N/A 
    
Foretinib     N/A    N/A     N/A 
    
Nilotinib 
 
 Grapefruit ↑ nilotinib AUC (293) 
 Imatinib ↑ nilotinib IUR (294) 
 Ketoconazole ↑ nilotinib AUC (295) 
 Rifampicin ↓ nilotinib AUC (295) 
 
 May be substrate of 
OATP1B1 and 
OATP1B3 (44) 
 Inhibitor of OCT1-3 
(185,267) 
 Rifampicin inhibits 
OATP1B1 and 
OATP1B3(272) 
 Ranitidine inhibits 
OCT1-3 (273) 
    
Bosutinib 
 
 Bosutinib ↑ digoxin AUC (296) 
 Ketoconazole ↑ bosutinib AUC (297) 
 Lansoprazole ↓ bosutinib AUC (296) 
 Rifampicin ↓ bosutinib exposure (296) 
 
   N/A     N/A 
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narrow therapeutic range, so it is important to prevent drug interactions or detect them 
early (299). All TKIs approved for the treatment of cancer are administered orally, 
which is highly convenient for the patient compared with conventional 
chemotherapeutics that are usually administered intravenously (301). However, oral 
delivery often results in less control over the toxicity profiles of TKIs and increased 
opportunities for drug-drug interactions. Table 1.2 highlights some of the important 
known interactions of TKIs with coadministered drugs, or food, such as grapefruit 
juice, which alter the exposure (AUC) or intracellular uptake (IUR) of either the TKIs 
or the drugs they are taken with. Extreme variations have been demonstrated in 
gefitinib and lapatinib AUCs which may contribute to the fluctuation in their 
anticancer pharmacodynamic effect (301). As shown in this table, several TKIs which 
are known or postulated to be substrates of OATP1B1 and OATP1B3 also have 
interactions with rifampicin, a known substrate and inhibitor of these transporters 
(123), where the outcome is decreased systemic exposure to the TKI. Since 
transporter inhibition is usually associated with an increase in AUC and reduced 
cellular uptake, it is probable that rifampicin is interacting with TKIs at a different 
site, for example CYP3A4, the hepatic drug metabolising enzyme which rifampicin 
has been demonstrated to strongly induce (123).  
 
While most patients tolerate TKIs, resistance to these compounds frequently develops 
and adverse reactions are evident in a subset of individuals. TKIs are primarily used at 
a fixed dose, which may result in suboptimal treatment or excessive toxicity, 
considering the wide interindividual variability in the pharmacokinetics of these 
therapies (301). The most common adverse events associated with TKI treatment 
include cutaneous toxicity (rash), hypertension, thyroid dysfunction, diarrhoea, 
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hepatotoxicity, cardiotoxicity and nephrotoxicity (194,301,302). Whether these 
toxicities arise from TKI-drug interactions at CYP enzymes or transporters is not 
determined.  The severity of several cutaneous side effects, for example hand-foot 
skin reaction, is suggested to be dose-dependent (303), which supports the possible 
need for dose individualisation of TKIs (301). 
 
Disparity exists between the toxicity profiles of TKIs because of the different kinases 
they target (303). Clinical experience has revealed that inhibition of VEGFR induces 
several side effects including hypertension and renal and cardiac toxicity (304). 
Additionally, inhibitors of HER2 are associated with cardiac dysfunction, while 
inhibition of EGFR has been correlated with significant dermatologic and liver 
toxicity (194).  
 
The observed variability in TKI efficacy and toxicity may also be due to genetic 
polymorphisms, age, gender, ethnicity, disease state, and organ function, among other 
factors (305). Approximately 20 to 30% of adverse reactions to drugs are assumed to 
be caused by interactions between drugs (306). Accordingly, the current EMA 
guideline and FDA draft guidance for drug interaction studies call for mandatory 
pharmacokinetic studies in clinical trials of new drugs (76,77). Using in vitro-in vivo 
extrapolation methods such as those suggested for SLCs by the International 
Transporter Consortium (ITC), many interactions can be discovered or predicted (27). 
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1.3 Specific aims of the project 
 
Excluding inhibition studies of the organic cation transporters (185), little research 
has been conducted to assess TKIs for their capacity to inhibit other human solute 
carriers in the SLCO and SLC22 families. Considering the broad range of 
pharmaceutical compounds that have been established as substrates of these 
transporters, and the likelihood of several anticancer and palliative drugs being 
concomitantly administered, there is the potential for adverse effects arising from 
transporter-mediated drug-drug interactions. Moreover, modulation of drug uptake, 
for example by drug-drug interactions occurring at hepatic influx transporters, may 
also affect their intracellular metabolism by CYP enzymes (307). This project was 
designed to investigate the inhibitory capabilities of 13 different TKIs and five 
metabolites of the TKI sorafenib on 13 members of the SLC superfamily of 
transporters. The transporters evaluated include OATP1A2, OATP1B1, OATP1B3, 
OATP2B1, OAT1-4, OCT1-3 and OCTNs 1 and 2. In vitro-in vivo extrapolation 
methods will be utilised to quantitatively assess the drug-drug interaction potential of 
TKIs with these important solute carriers. 
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Chapter 2 
 
Materials and Methods 
 
 
 
2.1 Materials 
 
2.1.1 TKI compounds 
 
Sorafenib and five metabolites of sorafenib, including N’-hydroxymethylsorafenib N-
oxide (M-1), sorafenib N-oxide (M-2), N’-hydroxymethylsorafenib (M-3), N’-
desmethylsorafenib (M-4),  N’-desmethylsorafenib N-oxide (M-5) were synthesised 
by Dr Tristan Rawling according to literature procedures (308-311). Reagents for the 
synthesis of sorafenib and its metabolites were obtained from Sigma-Aldrich (Castle 
Hill, New South Wales, Australia).  
 
Gefitinib, lapatinib, nilotinib, sunitinib, bosutinib, vandetanib, afatinib, cediranib, 
erlotinib, pelitinib, neratinib and foretinib were purchased from Selleck Chemicals 
(Houston, Texas, USA). 
 
2.1.2 Chemicals and reagents 
 
[
3
H]-estrone-3-sulfate (57.3 Ci/mmol), [
3
H]-CCK-8 (97.5 Ci/mmol), and [
3
H]-MPP
+
 
(82.1 Ci/mmol) were purchased from PerkinElmer (Melbourne, Victoria, Australia). 
[
3
H]-PAH (60 Ci/mmol), [
3
H]-L-ergothioneine (1.7 Ci/mmol), and [
14
C]-L-carnitine 
(56 mCi/mmol) were purchased from BioScientific Pty. Ltd. (Gymea, New South 
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Wales, Australia). HEK293 cells were obtained from the American Type Culture 
Collection (ATCC) and were frozen at passage number 4. Unless otherwise stated, all 
cell culture media and reagents were obtained from Invitrogen (Mount Waverley, 
Victoria, Australia). 
 
The plasmids incorporated with human OATP1A2 (reference sequence: 
NM_005075.1), OATP1B1 (reference sequence: AB026257.1), OATP1B3 (reference 
sequence: NM_019844), and OATP2B1 (reference sequence: NM_007256) 
complementary DNAs (cDNAs) were obtained from United BioResearch Pte Ltd. 
(Dural, New South Wales, Australia). Plasmids cloned with the open reading frames 
(ORFs) of human OAT1 (reference sequence: NM_004790.4), OAT2 (reference 
sequence: NM_006672.2), OAT3 (reference sequence: NM_004254.2), OCT1 
(reference sequence: NM_003057.2), OCT2 (reference sequence: NM_003058.2), and 
OCT3 (reference sequence: NM_021977.2) were purchased from Australian 
Biosearch (Balcatta, Western Australia, Australia). The plasmids of human OAT4 
were cloned in house as described in the literature (312). The plasmids containing the 
full-length human OCTN1 (reference sequence: NM_003059) and OCTN2 (reference 
sequence: NM_003060) cDNAs were obtained from Gene-Ethics (Asia) Pte Ltd. (The 
Franklin, Singapore).  
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2.2 Methods 
 
2.2.1 Expression of SLC transporters in HEK293 cells 
 
HEK293 cells were maintained at 37ºC in an atmosphere of 95% air and 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal 
bovine serum (FBS). All cells were sub-cultured twice a week and passage numbers 9 
to 37 were used throughout the study. Two days prior to performing the transport 
experiments, cells were seeded in 48-well human fibronectin-coated plates at a 
density of 250,000 cells/well. One day after seeding, cells were transfected with 0.32 
μg plasmid cDNA/well using Lipofectamine 2000 Reagent (Invitrogen) or DNAfectin 
2100 (Applied Biological Materials Inc., Richmond, British Columbia, Canada) 
following the manufacturer’s instructions. 24 hours after transfection, transport 
activities were measured. 
 
2.2.2 Transport studies 
 
Uptake of a mix of radiolabeled and unlabelled prototypical substrate of each SLC 
(see Table 2.1), was initiated at room temperature in phosphate-buffered saline (PBS), 
pH 7, containing 5 mM glucose. Total substrate concentrations and time used in the 
study were compatible with the previously determined time- and concentration-
dependent studies of these transporters: 300 nM [
3
H]-estrone-3-sulfate for OAT3, 
OAT4, OATP1A2, OATP1B1, and OATP2B1 (31,312-315); 2 μM [3H]-estrone-3-
sulfate for OAT2 at pH 5.5 (53); 5 μM [3H]-PAH for OAT1 (316); 2 nM [3H]-CCK-8 
for OATP1B3 (34); 100 nM [
3
H]-MPP
+
 for OCT1, OCT2, and OCT3 (317); 5 μM 
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[
3
H]-L-ergothioneine for OCTN1 (147); and 5 μM [14C]-L-carnitine for OCTN2 (159), 
respectively. Preliminary experiments indicated that initial rates of transporter-
mediated substrate uptake in HEK293 cells were linear over at least 8 minutes, which 
was the time selected for subsequent experiments. The uptake mixture, consisting of 
PBS solution, prototypical substrate and inhibitor (10 μM TKI or TKI metabolite 
dissolved in DMSO) was added to confluent cells upon removing media from the 
wells. The uptake was terminated by rapidly washing the cells in ice-cold PBS. The 
cells were then solubilised in 0.2 M NaOH and neutralised with 0.2 M HCl before 
aliquoting for liquid scintillation counting. The intracellular concentrations of model 
substrate were analysed with an Ultima Gold scintillation cocktail (PerkinElmer) 
using a PerkinElmer Tri-Carb 2810TR liquid scintillation analyzer. Uptake count was 
standardised to the amount of protein in each well (0.32 μg). In all experiments, 
untransfected cells were included on each plate to correct for passive permeability of 
the model substrate. The actual inhibition of uptake function of the transporter was 
calculated by subtracting the passive uptake counts in untransfected cells from the 
total uptake counts in the SLC-expressing cells according to the following equation: 
 
inhibition (%) =       
upta e (S   inhibitor) - upta e (untransfected)
upta e (S  -inhibitor) - upta e (untransfected)
     x 100                     [1] 
 
All experiments were performed on three separate occasions and each data group was 
conducted with triplicate wells (OATP1A2, OATP1B1, OATP1B3, OATP2B1, 
OAT1, OAT3, OAT4, OCTN1, OCTN2) or duplicate wells (OCT1-3, OAT2). Data 
are presented as the mean ± standard deviation. TKIs were classified as inhibitors and 
were further investigated if they reduced uptake of the prototypical substrate by more 
than 50%. This criterion for further inhibition analysis was selected in order to 
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account for potential error in transporter expression and efficiency of substrate uptake 
by cells within each well, for the purpose of avoiding false positives. 
 
2.2.3 IC50 studies 
 
The inhibitory potency of each compound was evaluated by determining their half 
maximal inhibitory concentration (IC50), i.e. the concentration of TKI required to 
reduce transporter-mediated uptake of prototypical substrate by 50%. Uptake 
measurements were performed by adding increasing concentrations of a particular 
TKI to the uptake buffer solution containing the relevant radiolabeled substrate at the 
concentrations indicated in Table 2.1. Different concentration ranges for each 
transporter-TKI interaction were chosen on the basis of the estimated 50% inhibitory 
concentration in the preliminary screening experiments. Experiments were repeated 
three times with triplicate wells for each data group on each occasion. Data are 
presented as the mean ± standard error. 
 
2.2.4 Kinetic studies 
 
 
For kinetic analysis, OATP1A2-transfected HEK293 cells were prepared for uptake 
studies as indicated in Section 2.2.2, however in place of a fixed concentration of 
estrone-3-sulfate in the upta e buffer solution, concentrations of 0.5 μM, 1 μM, 5 μM, 
10 μM, 15 μM and 30 μM were added to separate wells in duplicate (see Table 2.1). 
These concentrations were chosen in order to include the dissociation constant for the 
transporter-substrate complex (Km) for OATP1A2 and estrone-3-sulfate, which is 
approximately 15 μM. For each different concentration of estrone-3-sulfate, six 
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concentrations of cediranib were added to the uptake solution in duplicate; 0 nM, 10 
nM, 25, nM, 50 nM, 75 nM, 100 nM. The reactions were conducted as outlined in 
Section 2.2.2 and the uptake of estrone-3-sulfate was determined using liquid 
scintillation counting. Data are presented as the mean ± standard error. 
 
In the kinetic analysis of OATP2B1-mediated transport of estrone-3-sulfate, HEK293 
were prepared for uptake as outlined previously, however five different 
concentrations of estrone-3-sulfate (0.5 μM, 1 μM, 2 μM, 5 μM and 10 μM) were 
added to separate wells in duplicate (see Table 2.1). These concentrations were 
selected in order to include the dissociation constant for the transporter-substrate 
complex (Km) for OATP2B1 and estrone-3-sulfate, which is approximately 5 μM. For 
each different concentration of estrone-3-sulfate, six concentrations of erlotinib were 
added to the uptake solution in duplicate; 0 nM, 10 nM, 25, nM, 50 nM, 75 nM, 100 
nM. The reactions were conducted as outlined in Section 2.2.2 and the uptake of 
estrone-3-sulfate was determined using liquid scintillation counting. Results are given 
as the mean ± standard error. 
 
Substrate upta e rates were expressed as pmol/min/μg protein, using the following 
equations: 
 
specific activity of substrate =    
                                      
              
                    [2]                        
 
specific activity of transporter =   
                     -                 
                                                
    [3]             
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where pmol substrate is calculated from the substrate concentration (0.5 – 30 μM) 
used in 120 μ  upta e solution/well, min refers to the reaction time in minutes (8 
minutes), and μg protein is equal to 0.32 μg transporter cDNA/well. 
 
Experiment Transporter Prototypical substrate 
Concentration ratio 
radioabelled:unlabelled  (nM) 
 
Transport and 
IC50 studies 
 
OATP1A2, 
OATP1B1, 
OATP2B1,  
OAT3 
 
estrone-3-sulfate 
 
10:290 
  
OAT2 
 
estrone-3-sulfate 
 
20:1980 
 
 OAT4 estrone-3-sulfate 20:280 
 
 OATP1B3 CCK-8 2 (no unlabelled substrate) 
 
 
 OAT1 PAH 20:4980 
 
 OCT1  MPP
+
 
 
10:90 
 OCT2, OCT3 MPP
+
 
 
2:98 
 
 OCTN1 L-ergothioneine 200:4800 
 
 OCTN2 
 
L-carnitine 1000:4000 
    
 
Kinetic studies 
 
OATP1A2, 
OATP2B1  
 
estrone-3-sulfate 
 
10:490 (0.5 μM) 
10:990 (1 μM) 
10:1990 (2 μM) 
10:4990 (5 μM) 
10:9990 (10 μM) 
10:14990 (15 μM) 
10:29990 (30 μM) 
 
 
Table 2.1 Radiolabelled-to-unlabelled ratios of prototypical substrate used in uptake 
in preliminary screening experiments, IC50 determinations and kinetic tests. 
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2.3 Data analysis and statistics 
 
2.3.1 Statistics 
 
The statistical significance of differences between treatments in the preliminary 
screening experiments was evaluated using one-way analysis of variance (ANOVA) 
followed by Bonferroni’s multiple comparison test (p<0.05). The software used was 
Microsoft Excel and GraphPad Prism version 5.01 (GraphPad Inc., La Jolla, 
California, USA).  
 
2.3.2 IC50 determination 
 
 
IC50 values for each positive transporter-TKI inhibitory interaction were calculated by 
nonlinear regression models in GraphPad Prism. Nonlinear goodness-of-fit values 
(R
2
) for were also determined using this software. 
 
2.3.3 Kinetic analysis 
 
Kinetic parameters were calculated by applying the Michaelis-Menten equation to 
nonlinear regression analysis of the rate of transporter activity (V) and substrate 
concentration ([S]) in GraphPad Prism. Inhibitory data were further analysed using 
Lineweaver-Burk plots in conjunction with Dixon plots to determine the mode of 
TKI-mediated inhibition (318,319). Goodness-of-fit values (R
2
) for Lineweaver-Burk 
and Dixon replots were computed in GraphPad Prism. 
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Chapter 3 
 
Results 
 
 
 
3.1 Preliminary screening experiments 
 
 
With regard to elucidating the role of SLC proteins in TKI disposition, and the 
potential for drug-TKI interactions at transporter sites, 13 clinically important TKIs 
and five metabolites of the TKI sorafenib were tested for their capacity to inhibit the 
transport of specific SLC-mediated radiolabelled substrates into HEK293 cells. 
HEK293 cells were transfected with transporter cDNA to overexpress 13 different 
SLCs, including OATP1A2, OATP1B1, OATP1B3, OATP2B1, OAT1, OAT2, 
OAT3, OAT4, OCT1, OCT2, OCT3, OCTN1 and OCTN2. These SLCs constitute 
more than 50% of the functionally characterised members of the human SLCO and 
SLC22 families and are responsible for the uptake of important anticancer drugs such 
as imatinib, paclitaxel and cisplatin (40,43,61).  
 
The SLC-selective prototypical substrates used in these experiments were estrone-3-
sulfate for OATP1A2, OATP1B1, OATP2B1, OAT2, OAT3 and OAT4, CCK-8 for 
OATP1B3, PAH for OAT1, MPP
+
 for OCT1, OCT2 and OCT3, L-ergothioneine for 
OCTN1 and L-carnitine for OCTN2. The uptake of these substrates was quantified 
using liquid scintillation counting as mentioned earlier in Section 2.2.2. Results are 
given as the mean ± standard deviation. TKIs were considered to be significant 
inhibitors and were further investigated if they reduced uptake of the prototypical 
substrate by more than 50%. 
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(M) 
 
 
 
Figure 3.1 Inhibitory effects of TKIs on (A) OATP1A2-mediated estrone-3-sulfate 
uptake, (B) OATP1B1-mediated estrone-3-sulfate uptake, (C) OATP1B3-mediated 
CCK-8 uptake, (D) OATP2B1-mediated estrone-3-sulfate uptake, (E) OAT1-mediated 
PAH uptake, (F) OAT2-mediated estrone-3-sulfate uptake, (G) OAT3-mediated 
estrone-3-sulfate uptake, (H) OAT4-mediated estrone-3-sulfate uptake, (I) OCT1-
mediated MPP
+
 uptake, (J) OCT2-mediated MPP
+ 
uptake, (K) OCT3-mediated MPP
+ 
uptake, (L) OCTN1-mediated L-ergothioneine uptake, (M) OCTN2-mediated L-
carnitine uptake in HEK293 cells (n=3) in vitro. 13 TKIs and five metabolites of 
sorafenib were tested at a concentration of 10 μM. Statistically different from control: 
*p<0.05, **p<0.01, ***p<0.001. 
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As shown in Figure 3.1 (A), cediranib emerged as a highly potent selective inhibitor 
of OATP1A2-mediated estrone-3-sulfate uptake in HEK293 cells. The transporter 
activity was essentially abolished in the presence of 10 μM cediranib, while gefitinib, 
nilotinib, sunitinib, vandetanib, afatinib, erlotinib, pelitinib, neratinib and foretinib 
also showed more than 50% inhibition of estrone-3-sulfate uptake. Sorafenib and its 
five metabolites (M-1 to M-5), lapatinib and bosutinib did not show any inhibitory 
effect. Given that 10 μM is generally too high a concentration of TKI to achieve in 
vivo (the relevant therapeutic TKI Cmax,sys values vary between 0.08 μM to 9.90 μM; 
refs. 222,245,320-333), these positive interactions were repeated using a lower range 
of TKI concentrations to determine the half maximal inhibitory concentrations (IC50). 
 
 
Figure 3.1 (B) showed that no TKIs exerted major decreases in OATP1B1-mediated 
estrone-3-sulfate uptake in HEK293 cells, although small decreases were produced by 
the sorafenib metabolites M-1 and M-2.  
 
Erlotinib and neratinib emerged as effective inhibitors of CCK-8 uptake by 
OATP1B3-transfected HEK293 cells, as indicated by Figure 3.1 (C). Significant 
inhibitory interactions of sorafenib, a known substrate of this SLC, and gefitinib, 
nilotinib and vandetanib, which are potential substrates of OATP1B3 (44), were not 
apparent; hence these TKIs may utilise an alternative binding site from CCK-8. The 
interactions of OATP1B3 with erlotinib and neratinib were analysed further using a 
lower range of TKI concentrations to establish IC50 values. 
 
Gefitinib, nilotinib, afatinib, pelitinib and neratinib showed strong inhibitory effects 
on OATP2B1-mediated estone-3-sulfate uptake, as shown in Figure 3.1 (D); erlotinib 
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in particular emerged as a highly potent selective inhibitor of this transporter. The 
transporter activity was reduced by almost 100% in the presence of 10 μM erlotinib, 
while gefitinib, nilotinib, afatinib, pelitinib and neratinib also elicited more than 50% 
inhibition of estrone-3-sulfate uptake. Erlotinib-induced inhibition of OATP2B1 has 
been demonstrated previously (260), though in that study the authors used 20 μM 
erlotinib and further testing on this interaction was limited to obtaining an IC50 value 
(0.55 μM). Sorafenib and its five metabolites, lapatinib, sunitinib, bosutinib, 
vandetanib, cediranib and foretinib did not show any inhibitory effect. Since 10 μM is 
essentially unattainable during therapy in vivo, the positive interactions were repeated 
using a lower range of TKI concentrations to determine IC50 values. 
 
Figures 3.1 (E) and (F) demonstrate no inhibitory action of TKIs on OAT1-mediated 
PAH or OAT2-mediated transport of estrone-3-sulfate uptake in HEK293 cells, 
respectively. 
 
Nilotinib was found to be a potent inhibitor of OAT3-mediated estrone-3-sulfate 
uptake in HEK293 cells, as indicated by Figure 3.1 (G). Although not shown here, 
lapatinib has been previously identified as an inhibitor of OAT3 (92), however the 
concentration of lapatinib used in that study was 30 μM compared with 10 μM in this 
project, and even at this high concentration lapatinib only reduced estrone-3-sulfate 
uptake by 60%. Thus, it appears likely that lapatinib will not inhibit OAT3-mediated 
estrone-3-sulfate uptake at clinically relevant concentrations. Erlotinib has also been 
shown to interact with OAT3 as a substrate rather than an inhibitor (55), though this 
potential interaction was not indicated in Figure 3.1 (G). It is possible that erlotinib 
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enters cells via OAT3 using a different binding site to estrone-3-sulfate. No TKIs 
other than nilotinib inhibited OAT3 sufficiently for further IC50 analysis. 
 
Figure 3.1 (H) revealed no inhibitory effect of TKIs on OAT4-mediated estrone-3-
sulfate uptake in HEK293 cells. 
 
Bosutinib emerged as a potent inhibitor of OCT1-mediated transport in HEK293 cells, 
as indicated by Figure 3.1 (I), reducing the uptake of MPP
+
 by more than 75%. 
Gefitinib, nilotinib, sunitinib and erlotinib have been found previously to inhibit 
OCT1-, OCT2- and OCT3-mediated uptake of metformin (185). However, in the 
present study, only gefitinib and cediranib inhibited MPP
+
 uptake by nearly half (44% 
and 46%, respectively). As the criterion for further inhibition analysis was set at 50% 
reduction in model substrate uptake, an IC50 value was determined for bosutinib 
alone. 
 
Figures 3.1 (J), (K) and (L) demonstrate no inhibitory action of TKIs on OCT2- and 
OCT3-mediated MPP
+
 or OCTN1-mediated transport of L-ergothioneine uptake in 
HEK293 cells. Vandetanib has been shown to inhibit OCT2 transport of MPP
+
 and 
metformin (266), however the IC50 values that were calculated (73.4 μM and 8.8 μM 
respectively) are not clinically relevant. Erlotinib has also been shown to interact with 
OCT2 as a substrate (55), though this interaction was not observed in Figure 3.1 (J). 
As with OAT3, erlotinib may have a different binding site to MPP
+
. 
 
Cediranib was a moderate inhibitor of OCTN2, reducing uptake of L-carnitine in 
HEK293 cells by more than 50%, as indicated by Figure 3.1 (M). No other TKIs 
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appeared to have any effect on transporter uptake, hence further analysis to determine 
IC50 values was only undertaken for cediranib. 
 
Overall, 11 TKIs were found to inhibit the activity of particular transporters by more 
than 50%, comprising 21 significant inhibitory interactions. IC50 tests were performed 
for each of these interactions. 
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3.2 Determination of IC50 values for the inhibition of SLC-
mediated transport by TKIs 
 
From the preliminary screening tests it was determined that model substrate uptake by 
OATP1A2, OATP1B3, OATP2B1, OAT3, OCT1 and OCTN2 was inhibited by 11 
different TKIs. The corresponding IC50 values for these transporter-TKI inhibition 
interactions were calculated by fitting the data for increasing concentrations of TKI to 
a sigmoid dose-response regression curve using GraphPad Prism (Figures 3.2-7).  
 
All experiments were performed in triplicate and repeated on three independent 
occasions. Uptake of a fixed concentration of model substrate was measured in 
HEK293 cells overexpressing human transporter cDNA with the addition of six to 
eight increasing concentrations of TKI. Different concentration ranges for each 
transporter-TKI interaction were chosen on the basis of the estimated 50% inhibitory 
concentration in the preliminary screening experiments. The percentage of transporter 
activity remaining was plotted against each concentration of the inhibitor. Results are 
displayed as the mean ± standard error. 
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(I)       (J) 
 
 
 
Figure 3.2 Dose-response relationships for (A) afatinib, (B) cediranib, (C) erlotinib, 
(D) foretinib, (E) gefitinib, (F) neratinib, (G) nilotinib, (H) pelitinib, (I) sunitinib and 
(J) vandetanib with respect to inhibition of [
3
H]-estrone-3-sulfate uptake in HEK293-
OATP1A2 cells. Six to eight different TKI concentrations were used. 
 
Cediranib emerged as the most potent TKI inhibitor of OATP1A2-mediated estrone-
3-sulfate uptake, with an IC50 value of 35 nM. IC50 values derived for gefitinib and 
neratinib were also submicromolar, being 0.88 μM and 0.39 μM respectively, while 
afatinib, erlotinib and nilotinib inhibited OATP1A2 transport with IC50 values around 
1 μM. The interactions of sunitinib and vandetanib with OATP1A2 resulted in IC50 
values of 2.03 μM and 2.45, μM respectively, however given the very low Cmax,sys that 
sunitinib can achieve in vivo (329), it is unlikely this result is clinically relevant. IC50 
values for foretinib and pelitinib were more than 100-fold the IC50 for cediranib. 
Cediranib was identified as a candidate for further kinetic testing to determine the 
mode of inhibition (Section 3.3).  
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(A)         (B) 
 
 
 
 
Figure 3.3 Dose-response relationships for (A) erlotinib- and (B) neratinib-mediated 
inhibition of [
3
H]-CCK-8 uptake in HEK293-OATP1B3 cells. Six to seven different 
TKI concentrations were used. 
 
The IC50 value for neratinib-mediated inhibition of OATP1B3 substrate uptake was 
submicromolar (0.65 μM), while erlotinib inhibited this transporter slightly less 
effectively, with an IC50 of 1.19 μM. Both interactions are li ely significant in vivo as 
erlotinib has a particularly high unbound Cmax,sys (323,324). 
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(C)         (D) 
 
 
 
 
(E)       (F) 
 
 
 
 
Figure 3.4 Dose-response relationships for (A) afatinib, (B) erlotinib, (C) gefitinib, 
(D) neratinib, (E) nilotinib and (F) pelitinib with respect to inhibition of [
3
H]-
estrone3-sulfate uptake in HEK293-OATP2B1 cells. Six to seven different TKI 
concentrations were used. 
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Erlotinib emerged as the most potent TKI inhibitor of OATP2B1-mediated estrone-3-
sulfate uptake, with an IC50 value of 32 nM. This is 17-fold lower than the previously 
reported IC50 for this interaction (0.55 μM; ref. 260), though in that report, the 
concentration range used for erlotinib IC50 determination varied between 20 nM and 
400 μM. The present experiment used 0 nM to 100 nM which delivers a much more 
accurate estimate of IC50, since the range of percentage inhibitions are approximately 
symmetrical around the 50% inhibition point. The IC50 derived for gefitinib was also 
submicromolar (0.65 μM), while afatinib, neratinib, nilotinib and pelitinib inhibited 
OATP1A2 transport with IC50 values around 2-3 μM. Erlotinib was identified as a 
candidate for further kinetic evaluation to determine the mode of inhibition (Section 
3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Dose-response relationship for nilotinib-induced inhibition of [
3
H]-
estrone-3-sulfate uptake in HEK293-OAT3 cells. Seven different nilotinib 
concentrations were used. 
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Nilotinib was demonstrated to be a highly potent inhibitor of OAT3-mediated estrone-
3-sulfate uptake with an IC50 of 0.41 μM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Dose-response relationship for bosutinib-influenced inhibition of [
3
H]-1-
MPP
+
 uptake in HEK293-OCT1 cells. Seven different bosutinib concentrations were 
used. 
 
Bosutinib was shown to be a moderately effective inhibitor of OCT1-mediated MPP
+
 
uptake with an IC50 of 2.06 μM. Further analysis comparing this value with the 
Cmax,sys achieved by bosutinib is required to ascertain whether this is a clinically 
relevant interaction. 
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 Figure 3.7 Dose-response relationship for cediranib-induced inhibition of [
14
C]-L-
carnitine uptake in HEK293-OCTN2 cells. Seven different cediranib concentrations 
were used. 
 
Cediranib was a modest inhibitor of OCTN2-mediated L-carnitine uptake with an IC50 
of 2.49 μM. Further exploration comparing this value with the Cmax,sys for cediranib is 
needed to assess whether this result is clinically significant. 
 
Inhibitors were considered to be selective if their IC50 values were at least 10-fold 
lower than those of other transporters (260). Hence, cediranib was identified as a 
selective inhibitor of OATP1A2, as the IC50 for this interaction was more than 70-fold 
lower than the IC50 derived from cediranib-mediated inhibition of OCTN2. Consistent 
with previous findings (260), erlotinib was established as a specific inhibitor of 
OATP2B1. 
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Table 3.1 Summary of IC50 values for transporter-TKI interactions and corresponding 
goodness-of-fit values (R
2
) for the nonlinear regression curves in Figures 3.2-7 
calculated using GraphPad Prism software. 
 
Transporter 
 
TKI IC50 (μM) R
2 
 
 
OATP1A2 
 
 
Afatinib 
Cediranib 
Erlotinib 
Foretinib  
Gefitinib 
Neratinib  
Nilotinib 
Pelitinib  
Sunitinib 
Vandetanib 
 
 
1.17 
0.03 
1.10 
3.55 
0.88 
0.39 
1.46 
3.77 
2.03 
2.45 
 
0.99 
0.98 
0.99 
0.99 
0.99 
0.98 
0.97 
0.99 
0.99 
0.99 
OATP1B3 
 
 
Erlotinib 
Neratinib
 
 
1.19 
0.65 
0.99 
0.97 
 
OATP2B1 
 
 
Afatinib 
Erlotinib 
Gefitinib 
Neratinib 
Nilotinib 
Pelitinib 
 
2.08 
0.03 
0.65 
2.68 
2.67 
2.01 
0.99 
0.97 
0.98 
0.97 
0.98 
0.97 
 
OAT3 
 
Nilotinib 
 
0.41 0.99 
 
OCT1 
 
Bosutinib 2.06 0.99 
OCTN2 Cediranib 2.49 0.99 
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3.3 Kinetic study of the inhibitory effect of cediranib on 
OATP1A2-mediated estrone-3-sulfate uptake 
 
 
To further investigate the mode of OATP1A2 inhibition by cediranib, kinetic 
experiments were carried out using six inhibitor concentrations and six substrate 
concentrations. The results were analysed using graphical methods, as discussed 
earlier in Section 2.3.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Michaelis-Menten family of plots for [
3
H]-estrone-3-sulfate uptake in 
OATP1A2-transfected HEK293 cells. Experiments were performed with 0.32 μg 
transporter protein/well and inhibitor (cediranib) concentrations of 0 nM (●), 10 nM 
(■), 25 nM (▲), 50 nM (▼), 75 nM (♦) and 100 nM (○), with 0.5 – 30 μM of estrone-3-
sulfate [S]. V refers to the velocity of substrate uptake. 
V
, 
p
m
o
l/
m
in
/μ
g
 
[S], μM 
3.3.1 Michaelis-Menten graph of OATP1A2 activity at a range of cediranib concentrations 
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Figure 3.8 demonstrates the concentration-dependent inhibition of OATP1A2-
mediated estrone-3-sulfate uptake in HEK293 cells by cediranib. Michaelis-Menten 
plots provide useful parameters to describe the affinity of a transporter for its 
substrate and the rate of substrate uptake, which can be used in subsequent analysis 
for the determination of inhibition constants (Ki) from IC50 values. Ks (or Km) pertains 
to the dissociation constant of the transporter-substrate complex, while Vmax refers to 
the limiting maximal velocity that would be observed when all of the transporter is 
present as the transporter-substrate complex. The value for Vmax was obtained from 
the Michaelis-Menten plot and the value for Ks was determined from the Lineweaver-
Burk plot in the absence of inhibitor (cediranib = 0 nM). This analysis was conducted 
in OATP1A2-transfected HEK293 cells (n=3) in vitro (Vmax = 12,400 pmol estrone-3-
sulfate/min/μg protein, Ks = 5.3 μM). 
 
 
3.3.2 Lineweaver-Burk plots of the inhibition of OATP1A2-mediated estrone-3-sulfate 
uptake by cediranib 
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(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 
 
 
 
Figure 3.9 (A) Lineweaver-Burk plot for the inhibition of [
3
H]-estrone-3-sulfate 
uptake in OATP1A2-transfected HEK293 cells by cediranib. The transporter activity 
was determined at six concentrations of cediranib, including 0 nM (●), 10 nM (■), 25 
nM (▲), 50 nM (▼), 75 nM (♦) and 100 nM (○), and six concentrations of estrone-3-
sulfate [S]; 0.5 μM, 1 μM, 5 μM, 10 μM, 15 μM and 30 μM. (B) Primary replot of 
inhibitor concentrations versus Lineweaver-Burk plot slope data. 
 
The mode of substrate inhibition by cediranib can be inferred using graphical methods 
such as double reciprocal Lineweaver-Burk graphs (Figure 3.9) and Dixon plots 
(Figure 3.10). The intersection point of a family of plots presented on a double 
reciprocal graph, such as that in Figure 3.9 (A), is characteristic of inhibition 
behaviour. In this case, the family of plots intersect above the 1/[S]-axis and to the left 
of the 1/V-axis, suggesting that cediranib may inhibit OATP1A2-mediated uptake of 
S
lo
p
e
 
[I], nM -Ki 
83 
 
estrone-3-sulfate in a mixed fashion (334). Whereas the family of reciprocal plots for 
a competitive inhibitor intersect on the 1/V-axis, and a non-competitive inhibitor 
produces plots which converge on the 1/[S]-axis, mixed-type inhibition is a 
combination of both of these modes (334). 
 
By graphing the slopes of each Lineweaver-Burk plot against the inhibitor 
concentrations, as in the Figure 3.9 (B) replot, the equilibrium dissociation constant 
for the transporter-inhibitor complex (Ki) can be determined (334). Ki is a favourable 
inhibition parameter for in vitro-in vivo extrapolation compared with IC50, as it is a 
value independent of substrate concentration (335), while IC50 values change 
according to substrate concentration. From analysis of Figure 3.9 (B), the point of 
intersection with the x-axis is equal to -38 nM (R
2
 = 0.94), hence the Ki for the 
interaction between OATP1A2 and cediranib was calculated to be 38 nM. This 
indicates that cediranib is a potent mixed-type inhibitor and may exhibit a greater 
affinity for OATP1A2 than the substrate, estrone-3-sulfate (Ks = 5.3 μM).  
 
The Ki value determined is highly comparable with the corresponding IC50 for this 
inhibition (35 nM). Considering the Ki is only 3 nM different from the IC50 calculated 
previously, it is likely that this is a simple mixed inhibition system (335). 
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Dixon plots, which present the reciprocal velocity (1/V) of the reaction against 
inhibitor concentration [I], and replots of the slopes of Dixon plot lines versus 
reciprocal substrate concentration (1/[S]), were implemented to further clarify the 
mode of inhibition.  
 
 
3.3.3 Dixon plots of the inhibition of OATP1A2-mediated estrone-3-sulfate uptake by 
cediranib 
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(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 (A) Dixon plot for the inhibition of [
3
H]-estrone-3-sulfate uptake in 
OATP1A2-transfected HEK293 cells by cediranib (0-100 nM). Estrone-3-sulfate 
concentrations were 0.5 μM (●), 1 μM (■), 5 μM (▲), 10 μM (▼), 15 μM (♦) and 30 
μM (○). (B) Dixon plot slope replot versus reciprocal substrate (estrone-3-sulfate) 
concentration. 
 
The appearance of the Dixon plot intersection in Figure 3.10 (A) confirms the mixed-
type inhibition mode identified in previous analyses, as the family of plots intersect 
above the x-axis. Dixon plots for partial and most mixed-type inhibition systems are 
curved, however when the transporter-substrate-inhibitor complex (TSI) is not 
functional, Dixon plots tend to be linear (β=0, where β is the factor by which the rate 
of substrate uptake is altered by the inhibitor). The linearity of the relationship in 
S
lo
p
e
 
1/[S], μM 
S 
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Figure 3.10 (B) indicates that β is 0 in this system, while the α factor, which 
corresponds to the change in the dissociation constant of the transporter-substrate 
complex (Ks) when cediranib occupies OATP1A2, can be calculated from the x-
intercept of this replot. When α is greater than 1, the family of Dixon plots intersect 
above the horizontal axis, and the plot resembles that obtained for a competitive 
inhibitor, as is the case in Figure 3.10 (A). The α value (from -1/αKs at the x-intercept 
in part (B) of Figure 3.10 was determined to be 3.5 (R
2
 = 0.99). Therefore, the mode 
of cediranib-induced inhibition of OATP1A2-mediated estrone-3-sulfate uptake is 
best considered as linear mixed-type with a pronounced non-competitive component 
(334). 
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3.4 Kinetic study of the inhibitory effect of erlotinib on 
OATP2B1-mediated estrone-3-sulfate uptake 
 
 
To further investigate the mode of OATP2B1 inhibition by erlotinib, kinetic 
experiments were carried out using six inhibitor concentrations and five substrate 
concentrations. The results were analysed using graphical methods, as discussed 
earlier in Section 2.3.3.  
 
 
 
 
 
 
 
 
Figure 3.11 Michaelis-Menten family of plots for [
3
H]-estrone-3-sulfate uptake in 
OATP2B1-transfected HEK293 cells. Experiments were performed with 0.32 μg 
transporter protein/well and inhibitor (erlotinib) concentrations of 0 nM (●), 10 nM 
(■), 25 nM (▲), 50 nM (▼), 75 nM (♦) and 100 nM (○), with 0.5 – 10 μM of estrone-3-
sulfate [S]. V refers to the velocity of substrate uptake. 
 
3.4.1 Michaelis-Menten graph of OATP2B1 activity at a range of erlotinib concentrations 
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Figure 3.11 indicates that as erlotinib concentration increases, the rate of estrone-3-
sulfate uptake by OATP2B1-transfected HEK293 cells is slightly reduced. The value 
for Vmax was obtained from the Michaelis-Menten plot and the value for Ks was 
determined from the Lineweaver-Burk plot in the absence of inhibitor (erlotinib = 0 
nM). This analysis was conducted in OATP2B1-transfected HEK293 cells (n=3) in 
vitro (Vmax = 6,672 pmol estrone-3-sulfate/min/μg protein, Ks = 1.6 μM). 
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3.4.2 Lineweaver-Burk plots of the inhibition of OATP2B1-mediated estrone-3-sulfate 
uptake by erlotinib 
 
 
(A) 
 
 
 
 
(B) 
 
 
  
-Ki 
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Figure 3.12 (A) Lineweaver-Burk plot for the inhibition of [
3
H]-estrone-3-sulfate 
uptake in OATP2B1-transfected HEK293 cells by erlotinib. The transporter activity 
was determined at six concentrations of erlotinib, including 0 nM (●), 10 nM (■), 25 
nM (▲), 50 nM (▼), 75 nM (♦) and 100 nM (○), and five concentrations of estrone-3-
sulfate [S]; 0.5 μM, 1 μM, 2 μM, 5 μM, and 10 μM. (B) Primary replot of inhibitor 
concentrations versus Lineweaver-Burk plot slope data. 
 
The double reciprocal graph in Figure 3.12 (A) shows the family of plots intersecting 
above the 1/[S]-axis and to the left of the 1/V-axis, suggesting that erlotinib may 
inhibit OATP2B1-mediated uptake of estrone-3-sulfate in a mixed fashion (334). 
 
From Figure 3.12 (B), the x-intercept value is equal to -41 nM (R
2
 = 0.99), which 
corresponds to the Ki for the interaction between OATP2B1 and erlotinib (334). This 
indicates that erlotinib is a potent mixed-type inhibitor and may exhibit a greater 
affinity for OATP2B1 than the substrate, estrone-3-sulfate (Ks = 1.6 μM).  
 
The Ki value calculated is very similar to the corresponding IC50 for this inhibition (32 
nM). Considering the Ki is only 11 nM different from the IC50 determined previously, 
it is possible that this is a simple mixed inhibition system (335). 
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3.4.3 Dixon plots of the inhibition of OATP2B1-mediated estrone-3-sulfate uptake by 
erlotinib  
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
S 
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Figure 3.13 (A) Dixon plot for the inhibition of [
3
H]-estrone-3-sulfate uptake in 
OATP2B1-transfected HEK293 cells by erlotinib (0-100 nM). Estrone-3-sulfate 
concentrations were 0.5 μM (●), 1 μM (■), 2 μM (▲), 5 μM (▼), 10 μM (○). (B) Dixon 
plot slope replot versus reciprocal substrate (estrone-3-sulfate) concentration. 
 
The intersection point of the family of Dixon plots in Figure 3.13 (A) confirms the 
mixed-type inhibition mode postulated from previous analyses, as the plots meet 
above the x-axis. The Dixon replot in Figure 3.13 (B) is linear, so β is equal to 0. The 
α factor, corresponding to the change in Ks when erlotinib occupies OATP2B1, was 
determined from the x-intercept of the replot in Figure 3.13 (B) to be 1.5 (R
2
 = 0.99). 
Analogous to the nature of OATP1A2 inhibition by cediranib, the mode of erlotinib-
induced inhibition of OATP2B1-mediated estrone-3-sulfate uptake can be regarded as 
linear mixed-type with a pronounced non-competitive component (334). 
 
 
 
Table 3.2 Kinetic parameters of the inhibition of OATP1A2 and OATP2B1-mediated 
estrone-3-sulfate uptake by cediranib and erlotinib. These values were calculated 
from replots of the inhibition data using GraphPad Prism software. 
 
 
 OATP1A2-mediated  estrone-3-sulfate 
uptake inhibition by cediranib 
OATP2B1-mediated  estrone-3-sulfate 
uptake inhibition by erlotinib 
 
Ks 
 
5.3 μM 
 
1.6 μM 
Vmax 12,400 pmol substrate/min/μg protein 6,672 pmol substrate/min/μg protein 
Ki 38 nM 41 nM 
α 3.5 1.5 
β 0 0 
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Chapter 4 
 
Discussion 
 
 
4.1 Evaluation of results from screening experiments 
 
 
Cell-based assay systems using recombinant transporters that are transiently 
expressed in cell lines such as HEK293 are useful tools for characterising drug-
transporter interactions in vitro. The principal qualities which have made HEK293 
cells a popular choice to study membrane proteins include their simple reproduction 
and maintenance, responsiveness to transfection using a wide variety of methods, high 
efficiency of transfection and protein production, and dependable translation and 
processing of proteins, among other attributes (336). HEK293 cell monolayers were 
therefore employed to assess the potential of TKIs to inhibit substrate uptake by 
individual recombinant transporters from the SLCO and SLC22A gene families. 
 
4.1.1 Organic anion transporting polypeptides 
 
Ten potentially clinically significant inhibitors of OATP1A2 were identified from 
preliminary screening results, including afatinib, cediranib, erlotinib, foretinib, 
gefitinib, neratinib, nilotinib, pelitinib, sunitinib and vandetanib. At a concentration of 
10 μM, these TKIs inhibited estrone-3-sulfate uptake in HEK293 cells overexpressing 
OATP1A2 by more than 50%; cediranib essentially inhibited uptake completely. 
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No inhibitors of OATP1B1-mediated uptake of estrone-3-sulfate were identified. This 
contradicts the literature where lapatinib has been demonstrated to be an inhibitor of 
OATP1B1 (92), though in that study the authors used estradiol 17β-D-glucuronide as 
a prototypical substrate and Chinese hamster ovary (CHO) cells heterologously 
expressing human OATP1B1, which may explain the discrepancies.  
 
OATP1B1 has been shown to have biphasic kinetics for estrone-3-sulfate uptake, 
indicating the presence of two distinct components of substrate transport (33). This 
has been exemplified in the influence of the lipid-lowering drug gemfibrozil on 
OATP1B1-mediated transport of estrone-3-sulfate, where inhibition of substrate 
uptake by gemfibrozil was apparent only at low substrate concentration (10 nM) and 
not at high (3 μM) (31). It was concluded that gemfibrozil solely interferes with the 
high affinity component of OATP1B1, suggesting that estrone-3-sulfate may not be 
an ideal model substrate to use for OATP1B1 interaction studies. Since the 
concentration of estrone-3-sulfate used in this experiment was relatively high (300 
nM), it is possible that lapatinib is exclusively an inhibitor of the high affinity 
component on OATP1B1 for estrone-3-sulfate, otherwise it may only interfere with 
the binding site for estradiol 17β-D-glucuronide.  
 
Sorafenib has recently been identified as a substrate of OATP1B1 (44), though its 
interaction with this transporter was not evident in the present findings. Furthermore, 
gefitinib, nilotinib and sunitinib have been proposed as potential substrates for 
OATP1B1 (44), which was also not supported by the current data. It is possible these 
TKIs utilise a different binding site from estrone-3-sulfate for OATP1B1-mediated 
uptake.  
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In summary, use of estrone-3-sulfate as the model substrate for OATP1B1 uptake is a 
possible confounding factor for predictions of the interaction potential of this 
transporter. Estradiol 17β-D-glucuronide or another well-characterised OATP1B1 
substrate such as pitavastatin could be used in order to cover the different binding 
sites of OATP1B1 (31,34). 
 
Two OATP1B3 inhibitors of potential clinical relevance were identified from initial 
screening upta e tests: erlotinib and neratinib. At a concentration of 10 μM, these 
TKIs inhibited CCK-8 uptake in OATP1B3-HEK293 cells by more than 50%. 
 
Inhibitors of OATP2B1-mediated estrone-3-sulfate transport identified from 
screening results, included afatinib, erlotinib, gefitinib, neratinib, nilotinib and 
pelitinib. At a concentration of 10 μM, these TKIs reduced estrone-3-sulfate uptake in 
HEK293 cells overexpressing OATP2B1 by more than 50%, with erlotinib emerging 
as a potent inhibitor (only 2% uptake of estrone-3-sulfate). Different interacting sites 
for estrone-3-sulfate have also been described for OATP2B1. The transport of this 
substrate follows biphasic uptake kinetics with a high-affinity component (Km value 
of 1.8 μM) and a low-affinity component (Km value of 1.4 mM) (337). The Ks value 
of 1.6 μM calculated from Section 3.4 can be considered as Km in this situation, owing 
to the fact that the transporter-substrate complex is not functional (Dixon plots are 
linear; β=0), hence the turnover number, or kcat of the transporter is very low and Km 
approaches Ks (338). This Ks indicates that erlotinib probably inhibits the transport of 
this substrate by OATP2B1 at its high-affinity binding site. 
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4.1.2 Organic anion transporters 
 
No inhibitors of OAT1, OAT2 or OAT4-mediated model substrate uptake were 
identified, however, nilotinib (10 μM) was observed to strongly inhibit estrone-3-
sulfate transport by OAT3-HEK293 cells (only 19% uptake of estrone-3-sulfate).  
 
4.1.3 Organic cation transporters 
 
No inhibition of OCT2 or OCT3-mediated MPP
+
 uptake was observed in the 
preliminary screening tests, however, bosutinib (10 μM) was seen to substantially 
reduce substrate uptake by OCT1-HEK293 cells (only 24% uptake of MPP
+
).  
 
4.1.4 Organic zwitterion/cation transporters 
 
Cediranib emerged as a potential inhibitor of OCTN2, decreasing the uptake of L-
carnitine by more than 50% in OCTN2-HEK293 cells. OCTN1 did not appear to be 
inhibited by any TKIs. 
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4.2 In vitro-in vivo extrapolation of IC50 and Ki values 
 
TKIs that reduced the uptake of SLC-mediated prototypical substrate by more than 
50% were further investigated for their drug-drug interaction potential by determining 
their IC50 values. IC50 values are useful criteria as they can be applied in a number of 
in vitro-in vivo extrapolation algorithms, such as R value estimation (27), to predict 
the likely clinical significance of these inhibitory interactions. The R value refers to 
the change in systemic exposure of a transporter substrate in the presence of an 
inhibitor. An R value of 2 indicates a 2-fold increase in substrate exposure. In such 
forecasting methods, the steady-state Cmax,sys achieved by repeated administration of 
the maximum tolerated dose of TKI, is usually used to compare with the IC50 value.  
 
Another parameter than can be implemented in these calculations is the Ki, which is 
the dissociation constant for the transporter-inhibitor complex (TI). This value is 
determined from kinetic experiments analysed using Michaelis-Menten, Lineweaver-
Burk and Dixon plots (see Sections 3.3 and 3.4). Ki values can be predicted from IC50 
values and vice versa using Michaelis-Menten constants (Vmax and Km), which is 
useful because IC50 values are the most commonly used assessment of inhibitory 
interactions (335). 
 
Among the 13 TKIs tested and the five metabolites of sorafenib, 11 TKIs including 
afatinib, bosutinib, cediranib, erlotinib, foretinib, gefitinib, neratinib, nilotinib, 
pelitinib, sunitinib and vandetanib were assessed for IC50 determination, while the 
most potent inhibitors cediranib and erlotinib were subjected to kinetic analysis. 
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Recently, the ITC has proposed specific criteria for using in vitro data to predict 
potential in vivo drug-drug interactions occurring at SLCs important in drug 
disposition, in particular the OATPs, OATs and OCTs (27). Table 4.1 lists the 
transporter-TKI interactions that exceeded 50% inhibition of model substrate uptake 
in the preliminary screening tests and displays the IC50 values obtained, along with the 
Ki values from kinetic experiments. 
 
Cmax,sys values for TKIs, along with the fraction of unbound TKI in blood (i.e. the 
percentage of drug that is not bound to plasma proteins), were obtained from the 
literature (222,245,320-331) and compared with IC50 or Ki. If the IC50 is less than 10-
fold the unbound Cmax,sys in cells expressing OAT or OCT proteins (i.e. Cmax,sys/IC50 ≥ 
0.1), a clinical study to directly assess drug-drug interaction potential could be 
warranted (27).  
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Transporter 
 
TKI 
IC50  
(μM) 
 
Ki (μM) 
 
Unbound  
Cmax,sys 
(μM) 
References  
Clinical relevance:  
Unbound Cmax,sys/IC50 ≥  
(value) 
 
OATP1A2 
 
 
Afatinib 
Cediranib 
Erlotinib 
Foretinib 
a
 
Gefitinib 
Neratinib 
a
 
Nilotinib 
Pelitinib 
a
 
Sunitinib 
Vandetanib 
 
 
1.17 
0.03 
1.10 
3.55 
0.88 
0.39 
1.46 
3.77 
2.03 
2.45 
 
 
0.038 
 
 
 
0.009 
0.006   
0.424 
0.156 
0.069 
0.132 
0.085 
0.082 
0.007 
0.037 
 
(219,320) 
(321,322) 
(323,324) 
(245) 
(324,325) 
(222) 
(326,327) 
(328) 
(324,329) 
(330) 
 
No* 
Yes (0.17) 
Yes (0.39) 
No 
No*  
No*  
No* 
No 
No 
No* 
OATP1B3 
 
 
Erlotinib 
Neratinib
 a  
 
1.19 
0.65 
 0.424 
0.132 
(323,324) 
(222) 
 
Yes (0.36) 
No*  
OATP2B1 
 
 
Afatinib 
Erlotinib 
Gefitinib 
Neratinib
 a
 
Nilotinib 
Pelitinib
 a
 
 
2.08 
0.03 
0.65 
2.68 
2.67 
2.01 
 
0.041 
 
0.009 
0.424 
0.069 
0.132 
0.085 
0.082 
(219,320) 
(323,324) 
(324,325) 
(222) 
(326,327) 
(328) 
 
No*  
Yes (13) 
Yes (0.11) 
No* 
No* 
No 
OAT3 
 
Nilotinib 
 
0.41  0.085 
 
(326,327) 
 
Yes (0.21) 
OCT1 
 
Bosutinib 2.06  0.016 (296,331) No*  
 
OCTN2 Cediranib 2.49  0.006 (321,322) No 
0.1 
a
 Information regarding the unbound fraction of TKI in plasma is not reported, hence total Cmax,sys is given.  
* With respect to the estimated maximum concentration of unbound TKI at the inlet of the liver (185,339,340), these 
transporter-TKI inhibition interactions are also considered clinically significant (see Table 4.3). 
 
Table 4.1 Experimentally-determined IC50 and Ki values of TKI-mediated inhibition of transporter 
uptake, compared with clinically-derived unbound TKI Cmax,sys values.  
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As shown, nilotinib inhibited OAT3-mediated transport of estrone-3-sulfate 
sufficiently (unbound Cmax,sys/IC50 = 0.21) to be considered for subsequent clinical 
analysis with a sensitive substrate such as methotrexate (51,341). Concomitant use of 
nilotinib with substrates of OAT3 may elicit significant drug-drug interactions 
resulting in altered exposure or cellular uptake of the inhibited substrate. 
 
The procedure for OATPs is slightly more complex. If the above criterion is met 
(Cmax,sys/IC50 ≥ 0.1), it is advised that an in vitro-in vivo extrapolation method is 
employed, such as the R value approach. The R value method uses the maximal 
unbound drug concentration at the inlet of the liver (Cmax,portal) rather than the 
unbound Cmax,sys which refers to the maximum concentration of inhibitor in systemic 
circulation. Generally orally-administered drug concentrations are highest at the inlet 
of the liver, where the blood flow from the hepatic artery and portal vein meet 
(185,340), therefore use of the unbound Cmax,portal value can avoid false negative 
predictions of drug-drug interactions at transporters in the liver.  
 
Given that the majority of inhibitory interactions identified in this research involve 
hepatic transporters (OATP1A2, OATP1B3, OATP2B1, OCT1 and OCTN2), it 
seemed prudent to include the Cmax,portal value for TKIs in the analysis of these 
particular SLCs. Hence, the unbound Cmax,sys/IC50 ≥ 0.1 measure of significance was 
adapted to consider unbound TKI in portal plasma in order to identify other 
potentially clinically relevant interactions for further in vitro-in vivo extrapolation 
(Table 4.2).  
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The clinical maximum concentration of unbound TKI in portal plasma at the inlet of 
the liver (unbound Cmax,portal) was calculated using the following equation (339): 
 
Unbound Cmax,portal =  fu    max,sys + (fu /Rb)   Dose   Fa    ka 
                       Qh 
 
where fu is the unbound fraction of TKI in plasma, Rb is the blood-to-plasma 
concentration ratio, dose is the maximum oral dose given, Fa is the maximum oral 
bioavailability of TKI, ka is the absorption rate constant, and Qh is hepatic blood flow 
rate (1,500 mL per min; ref. 27). Unless otherwise specified, Fa and Rb were assumed 
to be 1 in the present study, while two values of ka were evaluated; 0.1 per min, which 
is the theoretical maximum value for ka taking gastric emptying into account (339), 
and 0.03 per min, suggested by the ITC (27). 
 
The fu values for foretinib, neratinib and pelitinib in systemic plasma are not available 
in the literature, however to err on the conservative side in the estimation of potential 
in vivo drug-drug-interactions effected by these TKIs, the unbound fraction 0.01 (1%, 
i.e. TKI is 99% bound to plasma proteins) can be used (77).  
 
 
 
 
 
 
 
 
[4] 
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TKI 
 
Cmax,portal  
(μM) 
Fraction 
absorbed (Fa) 
Dose (mg) Fraction 
unbound (fu) 
References  
 
Afatinib 
 
2.45 
 
1 
 
55 
 
0.05 
 
(27,77,219,320) 
 
Bosutinib 18.6 1 500 0.04 (27,77,296,331) 
 
Cediranib 1.54 1 30 0.03 (27,77,239,321,322) 
 
Erlotinib 10.6 0.6-1 150 0.07 (27,185,276,323,324, 
342-344) 
 
Foretinib 7.74 1 240 0.01 (27,77,245) 
 
Gefitinib
a
 8.58 0.59 225 0.09 (27,185,212,261,324, 
325) 
 
Neratinib 
 
11.6 
 
1 
 
320 
 
0.01 
 
(27,77,222) 
      
Nilotinib 13.6 0.31 800 0.02 (27,77,185,326,327, 
345,346) 
 
Pelitinib 3.29 1 75 0.01 (27,77,328) 
 
Sunitinib 0.85 1 50 0.05 (27,185,324,329) 
 
Vandetanib 13.2 1 300 0.065 (27,77,330) 
      
 
 
 
 
 
 
Table 4.2 Variables used for the calculation of unbound Cmax,portal and R values. 
 
 
Results that were not significant from initial analysis using Cmax,sys values (unbound 
Cmax,sys/IC50 << 0.1), included the interactions between OATP1A2 and foretinib, 
pelitinib and sunitinib, OATP2B1 and pelitinib, and OCTN2 and cediranib. Despite 
application of the default parameters (Fa = 1, ka = 0.1 per min) when calculating their 
maximum unbound portal plasma concentrations using the variables in Table 4.2, the 
IC50 values for these TKIs exceeded the estimated unbound Cmax,portal values by at 
least 10-fold and are therefore not considered clinically relevant. Hence, these 
interactions were excluded from Table 4.3. 
a
 Rb used = 0.76 (212) 
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Transporter 
 
TKI 
 
IC50  
(μM) 
Unbound 
Cmax,portal (μM) 
 
Unbound Cmax,portal/IC50 ≥ 0.1 
 
 
OATP1A2 
 
Afatinib 
Gefitinib
a
 
Neratinib 
Nilotinib
b
 
Vandetanib 
 
 
1.17 
0.88 
0.39 
1.46 
2.45 
 
0.123
c
 – 0.387
d
 
0.772 
0.116
c
 – 0.385
d
 
0.273 
0.857
c
 – 2.772
d
 
 
0.11 – 0.33 
0.88 
0.30 – 0.99 
0.19 
0.35 – 1.13 
OATP1B3 Neratinib 0.65 0.116
c
 – 0.385
d
 
 
0.18 – 0.59 
 
OATP2B1 Afatinib 
Neratinib 
Nilotinib
a
 
2.08 
2.68 
2.67 
0.387
d
 
0.385
d
 
0.273 
 
0.19 
0.14 
1.10 
 
OCT1 Bosutinib 2.06 0.745
c
 – 2.447
d
 0.36 – 1.19 
 
 
 
 
 
 
 
 
 
 
Table 4.3 Experimentally-determined IC50 values from TKI-mediated inhibition of 
transporter uptake, compared with estimated unbound TKI Cmax,portal values. 
 
As shown in Table 4.3, some of the SLC-TKI interactions, such as the inhibition of 
OATP2B1 by afatinib and neratinib, were only regarded as significant when utilising 
the higher limit of ka = 0.1 per min. All other interactions, however, were important at 
the lower criterion of ka = 0.03 per min, while the interactions between OATP1A2 and 
the TKIs gefitinib and nilotinib, and OATP2B1 and nilotinib resulted in unbound 
Cmax,portal/IC50 values greater than 0.1 using the minimum parameters known for these 
a
 Fa used = 0.59 (261); Rb used = 0.76 (212) 
b
 Fa used = 0.31 (345) 
c
 Unbound Cmax,portal determined using the parameter ka = 0.03 per min. 
d
 Unbound Cmax,portal determined using the parameter ka = 0.1 per min. 
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TKIs. For example, the absolute bioavailability (Fa) for gefitinib is 0.59 (59%) and 
the blood-to-plasma concentration ratio for this drug is 0.76 (212,261). The absolute 
bioavailability of nilotinib is not known, however it is estimated to be low 
(approximately 0.31 or 31%; ref. 345) owing to the evidence that systemic exposure 
to nilotinib is increased by 82% when the drug is given with a high-fat meal compared 
with the fasted state (324,326). So as not to overestimate the effect of nilotinib on 
OATP1A2- and OATP2B1-mediated estrone-3-sulfate uptake, the lower limit of 0.31 
was used for Fa. 
 
Inhibition of OCT1-mediated uptake of MPP
+
 by bosutinib produced unbound 
Cmax,portal/IC50 values of 0.36 and 1.19, with ka set to 0.03 per min and 0.1 per min 
respectively. With regard to the guidelines suggested for OCTs by the ITC (27), since 
the IC50 is less than 10 times the estimated unbound Cmax, a clinical drug-drug 
interaction study is recommended using a probe substrate that is likely to be co-
administered with bosutinib in a therapeutic setting, such as cisplatin or imatinib 
(347,348). 
  
Table 4.3 summarises all OATP-TKI interactions for which the IC50 values are less 
than 10-fold the estimated maximum unbound portal plasma concentrations, hence R-
extrapolation is recommended (27). Additionally, positive results from Table 4.1, 
where the criterion of unbound Cmax,sys/IC50 ≥ 0.1 was applied, also require further in 
vitro-in vivo evaluation by the R value paradigm. In particular, IC50 and Ki values for 
erlotinib-induced inhibition of OATP2B1 transport generated unbound Cmax,sys/IC50 or 
Ki values of 13 and 10 respectively; at least 2 orders of magnitude higher than the 
threshold value of 0.1. Consequently the concentration of erlotinib necessary to 
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significantly inhibit OATP2B1-mediated uptake of estrone-3-sulfate is 10 times lower 
than the maximum unbound concentration of erlotinib in the systemic circulation. 
Other interactions were not quite as pronounced, though sufficient to be considered 
for R value estimation, including OATP1A2 inhibition by the TKIs cediranib and 
erlotinib, OATP1B3 inhibition by erlotinib, and OATP2B1 inhibition by gefitinib. 
 
The R value can be calculated from the following equations (27): 
 
 
R = 1 + fu   Cmax,portal    
        IC50 
 
R = 1 + fu   Cmax,portal 
         Ki 
 
 
The criterion of R>2, indicating that the AUC or Cmax,sys of an OATP substrate is 
predicted to increase more than 2-fold in the presence of an inhibitor, is applied to all 
OATPs, although the FDA recommends that the limit be set at R>1.25 for OATP1B1 
and OATP1B3 (77). Hence, in this evaluation, an R value greater than 2 indicates that 
a clinical drug-drug interaction study is advised for OATP1A2 and OATP2B1 
inhibitors, while an R value of 1.25 or more suggests potential clinical relevance for 
OATP1B3 inhibitors. Using these parameters and equations 5 and 6, in addition to 
combining different values for the bioavailability (Fa = reported value if known, or 1) 
and absorption rate constant (ka = 0.03 per min or 0.1 per min; refs. 27,349), R values 
for TKI-mediated inhibition of model substrate uptake in three OATPs were 
calculated for use in comparisons with clinical data. 
 
[5] 
[6] 
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  R calculated using equation 3 R calculated using equation 4 Average 
   
ka = 0.03 
 
ka = 0.1 
 
ka = 0.03 
 
ka = 0.1 
 
           
                 
                
 
 
 
   
 
  
 
   
 
 
 
   
 
  
 
    
 
OATP TKI           
1A2 Afatinib  1.11 1.11     1.33  1.33     1.22 
 Cediranib  1.86 2.32     3.47  4.99     1.79 2.21    3.26 4.66 3.07 
 Erlotinib  1.67 1.87     2.34  3.01     2.22 
 Gefitinib  1.88 2.44     3.75  5.60     3.42 
 Neratinib  1.30 1.30     1.99  1.99     1.65 
 Nilotinib  1.19 1.41     1.43  2.38     1.60 
 Vandetanib  1.35 1.35     2.13  2.13     1.74 
1B3 Erlotinib  1.62 1.81     2.24  2.85     2.13 
 Neratinib  1.18 1.18     1.59  1.59     1.39 
2B1 Afatinib  1.06 1.06     1.19  1.19     1.13 
 Erlotinib  24.1 30.9     47.0  69.8     18.0 23.1    35.0 51.7 37.5 
 Gefitinib  2.18 2.93     4.69  7.18     4.25 
 Neratinib  1.04 1.04     1.14  1.14     1.09 
 Nilotinib  1.10 1.23     1.23  1.75     1.33 
 
 
 
Table 4.4 Assorted R values for TKI-mediated inhibition of OATP substrate uptake 
calculated using equations 3 and 4. 
 
4.2.1 Significance of findings 
 
Six novel inhibitory interactions of OATPs with TKIs could be predicted from Table 
4.4 (in bold). In addition, the interaction of OATP2B1 with erlotinib was elaborated 
upon to determine the R value for this inhibition. As shown in the above table, the 
latter interaction produced an average R value of 37.5, suggesting that the exposure of 
OATP12B1 substrates can be expected to increase 37.5-fold in the presence of 
erlotinib. Erlotinib has an absolute bioavailability between 60% and 100%, with an 
Fa = 
reported 
value 
Fa = 
reported 
value 
Fa = 
reported 
value 
Fa = 
reported 
value 
Fa = 1 
 
Fa =  1 
 
Fa =  1 
 
Fa = 1 
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estimated average of approximately 76% in cancer patients (350). Even using the 
lowest possible criteria in the R-extrapolation for this interaction (Fa = 0.6, ka = 0.03 
per min), produced an R value of 24 or 18, applying the IC50 and Ki values 
respectively. Therefore the exposure of OATP2B1 substrates is predicted to be 
enhanced at least 18-fold in the presence of erlotinib.  
 
The potential for drug-drug interactions is considerable, such that erlotinib is 
recommended for further clinical drug-drug interactions studies with drug substrates 
of OATP2B1. No anticancer drug substrates for this transporter have been reported to 
date, though co-treatment of erlotinib with statins is not infrequent (351). While 
commonly used to treat hypercholesterolemia, increasing evidence suggests that 
statins exert pleiotropic effects, independent of cholesterol reduction, including 
antiproliferative and antimetastatic properties (352). Concurrent treatment of the HCC 
cell line HepG2 with erlotinib has been shown to augment the antiproliferative effects 
of fluvastatin (353). Several statins, including atorvastatin, fluvastatin, pravastatin and 
pitavastatin, are OATP2B1 substrates (31,103,125,349). Accordingly, there is 
potential for erlotinib to affect the efficacy and toxicity of statins in therapy, which 
may be related to interference with OATP2B1-mediated transport of substrates, such 
as fluvastatin. 
 
The second potent inhibitor of OATP2B1, gefitinib, was determined to have an R 
value greater than 2, hence the presence of this drug can be predicted to increase the 
AUC or Cmax,sys of OATP2B1 substrates by at least 2-fold. Along with erlotinib, 
gefitinib can be added to the growing compendium of OATP2B1 interacting 
compounds. 
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Erlotinib was identified as a potentially significant inhibitor of OATP1B3. Neratinib 
is also an inhibitor of OATP1B3 of possible clinical relevance, however it is noted 
that the pharmacokinetic parameters used in this assessment were estimated and not 
measured. OATP1B3 is known to transport several anticancer drugs, including 
docetaxel, hydroxyurea, imatinib, methotrexate, paclitaxel, and the potent irinotecan 
metabolite, SN-38 (39,40,46-49). Erlotinib has been administered concomitantly with 
docetaxel, paclitaxel and irinotecan, though significant pharmacokinetic interactions 
have not been identified in vivo (354-356). Both erlotinib and neratinib are 
recommended for further clinical drug-drug interaction studies with sensitive 
OATP1B3 substrates, for example statins (27).  
 
The novel OATP1A2 inhibitors include cediranib, erlotinib and gefitinib (mean R 
values of 3.07, 2.22 and 3.42 respectively), and possibly vandetanib (mean R value of 
1.74). The absolute bioavailability of cediranib in human is unknown, though in rat it 
is around 60% (239). This value was used in the R value approximations in Table 4.4. 
The average R value calculated for vandetanib-induced inhibition of OATP1A2 
estrone-3-sulfate transport was less than 2. However applying the uppermost 
boundaries for the R equation parameters (Fa = 1, ka = 0.1 per min) produced an R 
value of 2.13, indicating this interaction has potential clinical significance and further 
drug-drug interactions studies are needed. 
 
Imatinib, methotrexate and hydroxyurea are anticancer drugs that are transported by 
OATP1A2 (39-41). There is potential for interactions between cediranib, erlotinib, 
gefitinib or vandetanib and these anticancer drugs, in addition to the many others drug 
substrates identified so far for OATP1A2 including numerous statins and 
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antihypertensive drugs (357). Inhibition of VEGFR by cediranib and vandetanib can 
lead to vasoconstriction, causing hypertension (226). Consequently, it is highly likely 
that antihypertensive drugs will be paired with cediranib and vandetanib in a 
therapeutic setting (358). The exposure and cellular uptake of OATP1A2 substrates, 
such as the antihypertensive drugs atenolol and celiprolol, may be altered by 
concomitant treatment with these VEGFR inhibitors. 
 
4.2.2 Appraisal of analytical techniques 
 
The use of estimated unbound hepatic inlet concentrations (Cmax,portal) of inhibitors has 
proven to be a reliable tool for the in vivo prediction of reversible inhibitor 
concentrations that are likely to elicit drug-drug interactions in CYP enzymes (359). 
In terms of transporters, it has been demonstrated that use of the Cmax,portal variable in 
the calculation of R values for hepatic OATP interactions has been successful in the 
classification of compounds into interacting and non-interacting drugs, which was in 
good agreement with reported clinical data (360). Nonetheless, predicting the 
magnitude of these interactions based on R values was less definitive. For more 
quantitative estimations, the contribution of additional factors, such as drug 
metabolising enzymes and efflux transporters needs to be considered (360). 
Additionally, calibration of the R values calculated in Table 4.4 using compounds 
with known clinical inhibition patterns in OATPs, such as statins, is required in order 
to fully comprehend the drug-drug interaction potential of these TKIs. 
 
 
 
 
110 
 
4.3 Kinetic analysis of the inhibitory effect of cediranib and 
erlotinib on OATP1A2 and OATP2B1  
 
In the analysis of results from the kinetic experiments described in Section 3.3, the Ki 
value for the cediranib-induced inhibition of estrone-3-sulfate uptake in OATP1A2-
transfected HEK293 cells was calculated to be 38 nM. The corresponding Ks value for 
this interaction was found to be 5.3 μM. As the Ki is indicative of the binding affinity 
of the transporter for an inhibitor, and Ks is interpreted as the binding affinity between 
the substrate and transporter, it can be deduced that cediranib has approximately 140-
times greater affinity for OATP1A2 compared with the prototypical substrate estrone-
3-sulfate.  
 
In Section 3.4, the Ki value for the erlotinib-effected inhibition of estrone-3-sulfate 
transport in OATP2B1-transfected HEK293 cells was calculated to be 41 nM. The 
related Ks value for estrone-3-sulfate upta e was measured as 1.6 μM. From these 
parameters, it can be interpreted that OATP2B1 has almost 36-times greater affinity 
for erlotinib than for estrone-3-sulfate. As mentioned previously, it would appear that 
erlotinib inhibits the high affinity binding site on OATP2B1 for estrone-3-sulfate by a 
mixture of partial competitive and pure non-competitive inhibition modes (see 
Sections 3.4 and 4.1) (334). Erlotinib was identified as a selective inhibitor of 
OATP2B1, because the IC50 for this interaction was more than 10-fold lower than the 
IC50 values for the other OATPs (260). 
 
The kinetic analyses of these inhibitory interactions indicated that the mode of 
inhibition was linear mixed-type with a pronounced non-competitive component in 
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both cases (334). In this system, the β factor is equal to 0 and the transporter-
substrate-inhibitor complex (TSI) between OATP-estrone-3-sulfate-TKI is not 
functional. In non-competitive inhibition, the inhibitor binds to both unbound (T) and 
substrate-bound transporter (TS); likewise in mixed-type inhibition, the inhibitor can 
bind to T and TS, but also may overlap with the substrate-binding site, as seen in 
competitive inhibition. The equilibria describing this system are shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic of the equilibria between OATP (T), substrate (S) and inhibitor 
(I) for linear mixed-type inhibition adapted from (334) with minor modifications. In 
this case, S = estrone-3-sulfate and I = cediranib or erlotinib (TKI). 
 
 
As long as the inhibitor is present, some of the transporter will always be in the non-
productive TSI form, even at infinitely high substrate concentration. Furthermore, at 
any concentration of inhibitor, a portion of the transporter that is available for 
combination with estrone-3-sulfate will exist in the lower affinity protein-inhibitor 
complex form (TI). At an infinitely high concentration of inhibitor, all of the protein 
can be directed to the TI and TSI forms. Given that TSI is non-productive, the 
velocity of the uptake reaction can be driven to zero by increasing the inhibitor 
concentration. This explanation is consistent with the double reciprocal Lineweaver-
Ks 
Ki 
αKi 
kp 
αKi 
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Burk plots presented in Figures 3.9 (A) and 3.12 (A), where increasing concentration 
of inhibitor results in increasing slopes and 1/V-axis intercepts. 
 
4.3.1 Significance of findings 
 
Cediranib is a highly potent and selective VEGF signalling inhibitor with activity 
against all three VEGFRs and has demonstrated encouraging antitumour activity in 
early clinical studies across a broad range of tumours, both as monotherapy and in 
combination with certain chemotherapy regimens (239,361).  Although the clinical 
development of cediranib has been discontinued due to negative results in the 
treatment of HCC, NSCLC and bowel cancer (241), studies are ongoing in the 
investigation of its therapeutic effect on glioblastoma (243,244). VEGFR inhibitors 
such as cediranib and vandetanib have been associated with renal toxicity (304), 
which could be related to their inhibition of OATP1A2, given that this transporter is 
expressed at the luminal side of distal tubules of the nephron and may be involved in 
the secretion of toxins into urine (5). 
 
Cediranib is administered as a once-daily 30 mg dose which reaches an average 
Cmax,sys of approximately 0.2 μM (292,321,322,364-366). The maximal unbound 
plasma concentration of cediranib was determined to be 6 nM (323), indicating that 
this TKI has an unbound fraction of approximately 3% in blood. The absolute 
bioavailability in human is unknown for this drug, therefore in the previous R value 
calculation (Section 4.2.1), this variable was set to 1 (100% bioavailable). 60% 
bioavailability was also used in this calculation based on bioavailability in rat. 
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Erlotinib is an orally active, selective inhibitor of EGFR and has been approved for 
the therapy of advanced NSCLC and first-line treatment of metastatic pancreatic 
cancer in combination with gemcitabine (214). Augmented tumour growth inhibition 
has been reported when erlotinib is coadministered with paclitaxel and cisplatin (362), 
while concomitant treatment of this TKI with irinotecan in human colorectal cancer 
xenograft models was more effective than erlotinib alone (363). Both paclitaxel and 
the potent irinotecan metabolite SN-38 are known to be substrates of OATP1B3 
(48,49), which in this study was found to be significantly inhibited by erlotinib, hence 
it is possible that erlotinib alters the pharmacokinetics of these drugs by modulating 
their transmembrane transport. 
 
Erlotinib is given as a once-daily dose of 150 mg for the treatment of NSCLC or 100 
mg for pancreatic cancer, though for the in vivo-in vitro extrapolation for erlotinib-
induced interactions, the maximum tolerated dose (150 mg) was used to calculate 
Cmax,portal. The maximum unbound concentration of erlotinib in systemic plasma is 
0.424 μM (185), and its absolute bioavailability ranges from 60% to 100% depending 
on the fed or fasted state of patients (342). Erlotinib is highly bound to albumin and 
α1-acid glycoprotein in the blood resulting in a rather low unbound fraction of drug in 
plasma (7%). 
 
In the present study, the IC50 values for cediranib and erlotinib, against OATP1A2- 
and OATP2B1-mediated uptake of estrone-3-sulfate, were calculated to be 35 nM and 
32 nM  respectively.  Applying  the  parameters  detailed  in  Table 3.2,  the following  
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equation for mixed-type inhibition can be rearranged to determine Ki from IC50 for 
comparison with the experimentally-derived values (335): 
 
 
 
 
Using equation 7, where the Ks and α value were 5.3 μM and 3.5 respectively for the 
interaction between OATP1A2 and cediranib, while for OATP2B1 and erlotinib, the 
values for Ks and α were 1.6 μM and 1.5, the theoretical in vivo Ki values were 
determined as 34 nM (cediranib) and 28 nM (erlotinib). These values are comparable 
with the experimentally determined Ki values of 38 nM and 41 nM correspondingly. 
Considering the unbound Cmax,portal is predicted to be 46 nM for cediranib and 724 nM 
for erlotinib, these TKIs are able to inhibit OATP1A2 and OATP2B1 at 
concentrations that may be observed after oral doses of the drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+   
 
 Ks [S] 
[S] + Ks 
 Ki αKi 
 
IC50 = [7] 
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Chapter 5 
 
Conclusions and Directions for Future Work 
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5.1 Conclusion 
 
 
The present research identified six novel inhibitors of OATPs and one novel inhibitor 
of each of OAT3 and OCT1 at clinically relevant concentrations. These interactions 
included: the inhibition of OATP1A2-mediated estrone-3-sulfate uptake by cediranib, 
erlotinib and gefitinib; the inhibition of OATP1B3-mediated CCK-8 uptake by 
erlotinib and neratinib; the inhibition of OATP2B1-mediated estrone-3-sulfate uptake 
by erlotinib and gefitinib; the inhibition of OAT3-mediated estrone-3-sulfate uptake 
by nilotinib; and the inhibition of OCT1-mediated MPP
+
 uptake by bosutinib. All are 
recommended for further clinical drug-drug interaction studies with SLC-specific 
drug substrates. 
 
Using the in vitro-in vivo R value extrapolation approach recommended by the ITC, 
the inhibition of OATP2B1-mediated uptake by erlotinib was found to be particularly 
potent, with an R value of at least 18, suggesting that the systemic exposure to 
OATP2B1 substrates might be increased substantially in the presence of erlotinib. 
This has serious implications for the in vivo use of erlotinib as it may change the 
pharmacokinetics of OATP2B1 substrates, including some statins. 
 
 
Kinetic testing was implemented to determine the mode of inhibition for the highly 
potent interactions of OATP1A2 with cediranib and OATP2B1with erlotinib, which 
was linear-mixed in both cases. Cediranib has approximately 140-times greater 
affinity for OATP1A2 compared with the prototypical substrate estrone-3-sulfate, 
therefore it could be used as a selective inhibitor in clinical drug-drug interaction 
studies for this transporter. Erlotinib has almost 36-times greater affinity for 
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OATP2B1 than estrone-3-sulfate and is postulated to bind at the high affinity binding 
site for this substrate on OATP2B1 in a mixed-type fashion. 
 
SLCs contribute to the disposition of a broad spectrum of endogenous and exogenous 
compounds. Thus, inhibition of these transporters by TKIs may alter the 
pharmacokinetics and toxicities of concurrently administered drugs, including 
numerous anticancer drugs. Besides their expression in normal tissues, it is significant 
to note that several studies have shown altered tissue distribution of SLCs in some 
malignant tissues, hence substrate uptake into tumour cells could be modulated by the 
TKIs that were found to be inhibitory in the present study. 
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5.2 Limitations and recommendations for future work 
 
 
While several TKIs were found to be inhibitors of SLCs, whether they were also 
substrates was not assessed. Further uptake screening experiments using radiolabelled 
TKIs would be useful. Moreover, several TKIs are established in the literature as SLC 
substrates, but were not found to interact with the relevant transporters in this thesis. 
Therefore, standardised assays using a variety of substrates at different concentrations 
and pH would add to the present findings and reduce interlaboratory variability. 
 
Many challenges remain in mimicking the in vivo situation using in vitro experiments. 
Single-transfected cell uptake assays are limited in their ability to simulate the 
dynamic interplay between endogenous enzymes and transporters, and the possible 
compensatory increase in activities of one or more other transporters when the 
function of a transporter is suppressed. To assist the interpretation of the present data, 
polarised cells that stably express multiple transporters would be useful. For example, 
cells transfected with a recombinant uptake transporter in the basolateral membrane 
and an efflux transporter in the apical membrane, could be informative. Ideally, low 
passage cell lines expressing the full complement of drug transporters present in a 
given tissue or cell should be used, such as in primary cell-based assays. By adopting 
improved methods of evaluating transporter activity, and accounting for the 
contribution of drug metabolising enzymes and albumin to TKI disposition, enhanced 
quantification of potential in vivo drug-drug interactions will be possible to predict.  
 
The possibility of TKIs acting as allosteric stimulators of SLC uptake activity was 
outside the scope of this project but could be evaluated in future studies. 
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